{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:15:04Z","timestamp":1794809704825,"version":"4.9.1"},"reference-count":423,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"publisher","award":["IUF LAFDIL"],"award-info":[{"award-number":["IUF LAFDIL"]}],"id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) is an increasingly prevalent and deadly disease that is initiated by different etiological factors, such as alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, and other hepatotoxic and hepatocarcinogenic agents. The tumor microenvironment (TME) of HCC is characterized by several different fibroblastic and immune cell types, all of which affect the initiation, progression and metastasis of this malignant cancer. This complex immune TME can be divided into an innate component that includes macrophages, neutrophils, dendritic cells, myeloid-derived suppressor cells, mucosal-associated invariant T cells, natural killer cells, natural killer T cells, and innate lymphoid cells, as well as an adaptive component that includes CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells, CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, regulatory T cells, and B cells. In this review, we discuss the latest findings shedding light on the direct or indirect roles of these immune cells (and fibroblastic-like cells such as hepatic stellate cells) in the pathogenesis of HCC. Henceforth, further characterization of this heterogeneous TME is highly important for studying the progression of HCC and developing novel immunotherapeutic treatment options. In line with this, we also review novel groundbreaking experimental techniques and animal models aimed at specifically elucidating this complex TME and discuss emerging immune-based therapeutic strategies intended to treat HCC and predict the efficacy of these immunotherapies.\n                  <\/jats:p>","DOI":"10.1038\/s41423-025-01308-4","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:21:40Z","timestamp":1749601300000},"page":"1132-1158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy"],"prefix":"10.1038","volume":"22","author":[{"given":"Deniz","family":"Seyhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0505-2972","authenticated-orcid":false,"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-1174","authenticated-orcid":false,"given":"Fouad","family":"Lafdil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"1308_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, De Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"key":"1308_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410.","journal-title":"JAMA Surg"},{"key":"1308_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.trecan.2021.01.012","volume":"7","author":"V Leone","year":"2021","unstructured":"Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver inflammation and hepatobiliary cancers. Trends Cancer. 2021;7:606\u201323.","journal-title":"Trends Cancer"},{"key":"1308_CR5","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650\u201366.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1308_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","journal-title":"J Hepatol"},{"key":"1308_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176345","volume":"134","author":"B Mackowiak","year":"2024","unstructured":"Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Investig. 2024;134:e176345.","journal-title":"J Clin Investig"},{"key":"1308_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37\u201349.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1308_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1308_CR10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"1308_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4254\/wjh.v13.i4.393","volume":"13","author":"M Vij","year":"2021","unstructured":"Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: an update. World J Hepatol. 2021;13:393\u2013410.","journal-title":"World J Hepatol"},{"key":"1308_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101328","volume":"4","author":"WL Do","year":"2023","unstructured":"Do WL, Wang L, Forgues M, Liu J, Rabibhadana S, Pupacdi B, et al. Panviral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cell Rep Med. 2023;4:101328.","journal-title":"Cell Rep Med"},{"key":"1308_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ijc.35034","volume":"155","author":"B Pupacdi","year":"2024","unstructured":"Pupacdi B, Loffredo CA, Budhu A, Rabibhadana S, Bhudhisawasdi V, Pairojkul C, et al. The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand. Int J Cancer. 2024;155:1387\u201399.","journal-title":"Int J Cancer"},{"key":"1308_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","volume":"32","author":"J Chaisaingmongkol","year":"2017","unstructured":"Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017;32:57\u201370.e3.","journal-title":"Cancer Cell"},{"key":"1308_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ajpath.2024.10.013","volume":"195","author":"V Putatunda","year":"2025","unstructured":"Putatunda V, Jusakul A, Roberts L, Wang XW. Genetic, epigenetic, and microenvironmental drivers of cholangiocarcinoma. Am J Pathol. 2025;195:362\u201377.","journal-title":"Am J Pathol"},{"key":"1308_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","volume":"562","author":"M Seehawer","year":"2018","unstructured":"Seehawer M, Heinzmann F, D\u2019Artista L, Harbig J, Roux PF, Hoenicke L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018;562:69\u201375.","journal-title":"Nature"},{"key":"1308_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113446","volume":"42","author":"AJ Craig","year":"2023","unstructured":"Craig AJ, Silveira MAD, Ma L, Revsine M, Wang L, Heinrich S, et al. Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing. Cell Rep. 2023;42:113446.","journal-title":"Cell Rep"},{"key":"1308_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386\u2013401.","journal-title":"Nat Cancer"},{"key":"1308_CR19","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1158\/0008-5472.CAN-20-0225","volume":"80","author":"Y Midorikawa","year":"2020","unstructured":"Midorikawa Y, Yamamoto S, Tatsuno K, Renard-Guillet C, Tsuji S, Hayashi A, et al. Accumulation of molecular aberrations distinctive to hepatocellular carcinoma progression. Cancer Res. 2020;80:3810\u20139.","journal-title":"Cancer Res"},{"key":"1308_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-pathmechdis-111523-023520","volume":"20","author":"L Ma","year":"2025","unstructured":"Ma L, Li CC, Wang XW. Roles of cellular neighborhoods in hepatocellular carcinoma pathogenesis. Annu Rev Pathol Mech Dis. 2025;20:169\u201392.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"1308_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2020.11.036","volume":"74","author":"S Heinrich","year":"2021","unstructured":"Heinrich S, Craig AJ, Ma L, Heinrich B, Greten TF, Wang XW. Understanding tumor cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. J Hepatol. 2021;74:700\u201315.","journal-title":"J Hepatol"},{"key":"1308_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16\u201325.","journal-title":"Curr Opin Immunol"},{"key":"1308_CR23","doi-asserted-by":"crossref","unstructured":"Yao C, Wu S, Kong J, Sun Y, Bai Y, Zhu R, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biol Med. 2023;20:25\u201343.","DOI":"10.20892\/j.issn.2095-3941.2022.0449"},{"key":"1308_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology. Nat Commun. 2013;4:2823.","journal-title":"Nat Commun"},{"key":"1308_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1308_CR26","doi-asserted-by":"crossref","unstructured":"Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. In: Terjung R, editor. Comprehensive physiology [Internet]. 1st ed. Wiley; 2013 [cited 2024 Sep 30]. [1473\u201392 p.]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cphy.c120035.","DOI":"10.1002\/cphy.c120035"},{"key":"1308_CR27","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41590-020-0741-2","volume":"21","author":"V Koliaraki","year":"2020","unstructured":"Koliaraki V, Prados A, Armaka M, Kollias G. The mesenchymal context in inflammation, immunity and cancer. Nat Immunol. 2020;21:974\u201382.","journal-title":"Nat Immunol"},{"key":"1308_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2597-7","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Mi X, Wang Z, Zhang M, Hou J, Jiang S, et al. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway. Cell Death Dis. 2020;11:454.","journal-title":"Cell Death Dis"},{"key":"1308_CR29","doi-asserted-by":"publisher","first-page":"9671","DOI":"10.3390\/ijms24119671","volume":"24","author":"Q Pei","year":"2023","unstructured":"Pei Q, Yi Q, Tang L. Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities. Int J Mol Sci. 2023;24:9671.","journal-title":"Int J Mol Sci"},{"key":"1308_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/07357907.2016.1227442","volume":"34","author":"W Li","year":"2016","unstructured":"Li W, Miao S, Miao M, Li R, Cao X, Zhang K, et al. Hedgehog signaling activation in hepatic stellate cells promotes angiogenesis and vascular mimicry in hepatocellular carcinoma. Cancer Investig. 2016;34:424\u201330.","journal-title":"Cancer Investig"},{"key":"1308_CR31","doi-asserted-by":"crossref","unstructured":"Li S, Zhou B, Xue M, Zhu J, Tong G, Fan J, et al. Macrophage\u2010specific FGF12 promotes liver fibrosis progression in mice. Hepatology. 2023;77:816\u201333.","DOI":"10.1002\/hep.32640"},{"key":"1308_CR32","unstructured":"Xia Y, Wang Y, Xiong Q, He J, Wang H, Islam M, et al. Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC. Hepatology [Internet]. 2024 Jan 24 [cited 2024 Oct 5]; Available from: https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000762."},{"key":"1308_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cells8010016","volume":"8","author":"R Weiskirchen","year":"2019","unstructured":"Weiskirchen R, Tacke F. Relevance of autophagy in parenchymal and non-parenchymal liver cells for health and disease. Cells. 2019;8:16.","journal-title":"Cells"},{"key":"1308_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","volume":"18","author":"Y Filali-Mouncef","year":"2022","unstructured":"Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, DuPont N, Primard C, et al. The m\u00e9nage \u00e0 trois of autophagy, lipid droplets and liver disease. Autophagy. 2022;18:50\u201372.","journal-title":"Autophagy"},{"key":"1308_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","volume":"73","author":"J Bates","year":"2020","unstructured":"Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol. 2020;73:896\u2013905.","journal-title":"J Hepatol"},{"key":"1308_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03494-1","volume":"12","author":"Y Xia","year":"2021","unstructured":"Xia Y, Zhen L, Li H, Wang S, Chen S, Wang C, et al. MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway. Cell Death Dis. 2021;12:326.","journal-title":"Cell Death Dis"},{"key":"1308_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jhep.2021.12.019","volume":"76","author":"A Garrido","year":"2022","unstructured":"Garrido A, Kim E, Teijeiro A, S\u00e1nchez S\u00e1nchez P, Gallo R, Nair A, et al. Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis. J Hepatol. 2022;76:850\u201361.","journal-title":"J Hepatol"},{"key":"1308_CR38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41423-023-00983-5","volume":"20","author":"X Yang","year":"2023","unstructured":"Yang X, Li Q, Liu W, Zong C, Wei L, Shi Y, et al. Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023;20:583\u201399.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","volume":"610","author":"A Filliol","year":"2022","unstructured":"Filliol A, Saito Y, Nair A, Dapito DH, Yu LX, Ravichandra A, et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature. 2022;610:356\u201365.","journal-title":"Nature"},{"key":"1308_CR40","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s42255-022-00642-5","volume":"4","author":"QT Chen","year":"2022","unstructured":"Chen QT, Zhang ZY, Huang QL, Chen HZ, Hong WB, Lin T, et al. HK1 from hepatic stellate cell\u2013derived extracellular vesicles promotes progression of hepatocellular carcinoma. Nat Metab. 2022;4:1306\u201321.","journal-title":"Nat Metab"},{"key":"1308_CR41","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.3390\/ijms231810777","volume":"23","author":"PW Wang","year":"2022","unstructured":"Wang PW, Lin TY, Yang PM, Yeh CT, Pan TL. Hepatic stellate cell modulates the immune microenvironment in the progression of hepatocellular carcinoma. Int J Mol Sci. 2022;23:10777.","journal-title":"Int J Mol Sci"},{"key":"1308_CR42","first-page":"1","volume":"2019","author":"S Shao","year":"2019","unstructured":"Shao S, Duan W, Xu Q, Li X, Han L, Li W, et al. Curcumin suppresses hepatic stellate cell-induced hepatocarcinoma angiogenesis and invasion through downregulating CTGF. Oxid Med Cell Longev. 2019;2019:1\u201312.","journal-title":"Oxid Med Cell Longev"},{"key":"1308_CR43","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.7150\/thno.85369","volume":"13","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zhang L, Ma Y, Xie L, Yang Yyu, Jin C, et al. Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma. Theranostics. 2023;13:4430\u201348.","journal-title":"Theranostics"},{"key":"1308_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06077-4","volume":"14","author":"J Otto","year":"2023","unstructured":"Otto J, Verwaayen A, Penners C, Hundertmark J, Lin C, Kallen C, et al. Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice. Cell Death Dis. 2023;14:549.","journal-title":"Cell Death Dis"},{"key":"1308_CR45","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1053\/j.gastro.2020.12.015","volume":"160","author":"Y Myojin","year":"2021","unstructured":"Myojin Y, Hikita H, Sugiyama M, Sasaki Y, Fukumoto K, Sakane S, et al. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production. Gastroenterology. 2021;160:1741\u20131754.e16.","journal-title":"Gastroenterology"},{"key":"1308_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102151","volume":"47","author":"M Shen","year":"2021","unstructured":"Shen M, Li Y, Wang Y, Shao J, Zhang F, Yin G, et al. N6-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells. Redox Biol. 2021;47:102151.","journal-title":"Redox Biol"},{"key":"1308_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/cas.15605","volume":"114","author":"S Li","year":"2023","unstructured":"Li S, Hu X, Yu S, Yi P, Chen R, Huang Z, et al. Hepatic stellate cell\u2010released CXCL1 aggravates HCC malignant behaviors through the MIR4435\u20102HG\/miR \u2010506\u20103p\/TGFB1 axis. Cancer Sci. 2023;114:504\u201320.","journal-title":"Cancer Sci"},{"key":"1308_CR48","first-page":"5254","volume":"13","author":"C Sun","year":"2023","unstructured":"Sun C, Xu W, Xia Y, Wang S. PRDM16 from hepatic stellate cells-derived extracellular vesicles promotes hepatocellular carcinoma progression. Am J Cancer Res. 2023;13:5254\u201370.","journal-title":"Am J Cancer Res"},{"key":"1308_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217243","volume":"604","author":"Y Yu","year":"2024","unstructured":"Yu Y, Li Y, Zhou L, Cheng X, Gong Z. Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses. Cancer Lett. 2024;604:217243.","journal-title":"Cancer Lett"},{"key":"1308_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.27822","volume":"62","author":"J Ji","year":"2015","unstructured":"Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, et al. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology. 2015;62:481\u201395.","journal-title":"Hepatology"},{"key":"1308_CR51","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.apsb.2021.12.007","volume":"12","author":"P Luo","year":"2022","unstructured":"Luo P, Liu D, Zhang Q, Yang F, Wong YK, Xia F, et al. Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis by targeting peroxiredoxins and HO-1. Acta Pharm Sin B. 2022;12:2300\u201314.","journal-title":"Acta Pharm Sin B"},{"key":"1308_CR52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","volume":"20","author":"B Cogliati","year":"2023","unstructured":"Cogliati B, Yashaswini CN, Wang S, Sia D, Friedman SL. Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nat Rev Gastroenterol Hepatol. 2023;20:647\u201361.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1308_CR53","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep.31848","volume":"74","author":"S Wang","year":"2021","unstructured":"Wang S, Tang XT, Lin M, Yuan J, Peng YJ, Yin X, et al. Perivenous stellate cells are the main source of myofibroblasts and cancer\u2010associated fibroblasts formed after chronic liver injuries. Hepatology. 2021;74:1578\u201394.","journal-title":"Hepatology"},{"key":"1308_CR54","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","volume":"73","author":"M Song","year":"2021","unstructured":"Song M, He J, Pan Q, Yang J, Zhao J, Zhang Y, et al. Cancer\u2010associated fibroblast\u2010mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology. 2021;73:1717\u201335.","journal-title":"Hepatology"},{"key":"1308_CR55","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41388-022-02309-7","volume":"41","author":"YT Tsai","year":"2022","unstructured":"Tsai YT, Li CY, Huang YH, Chang TS, Lin CY, Chuang CH, et al. Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. Oncogene. 2022;41:3011\u201323.","journal-title":"Oncogene"},{"key":"1308_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"GQ Zhu","year":"2023","unstructured":"Zhu GQ, Tang Z, Huang R, Qu WF, Fang Y, Yang R, et al. CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9:25.","journal-title":"Cell Discov"},{"key":"1308_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05613-w","volume":"22","author":"W Tong","year":"2024","unstructured":"Tong W, Wang T, Bai Y, Yang X, Han P, Zhu L, et al. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment. J Transl Med. 2024;22:840.","journal-title":"J Transl Med"},{"key":"1308_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146987","volume":"131","author":"S Bhattacharjee","year":"2021","unstructured":"Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Investig. 2021;131:e146987.","journal-title":"J Clin Investig"},{"key":"1308_CR59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1535370219898141","volume":"245","author":"D Dhar","year":"2020","unstructured":"Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med. 2020;245:96\u2013108.","journal-title":"Exp Biol Med"},{"key":"1308_CR60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol Mech Dis. 2017;12:153\u201386.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"1308_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04418-9","volume":"12","author":"Z Liu","year":"2021","unstructured":"Liu Z, Mo H, Liu R, Niu Y, Chen T, Xu Q, et al. Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression. Cell Death Dis. 2021;12:1134.","journal-title":"Cell Death Dis"},{"key":"1308_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121003","volume":"276","author":"Z Li","year":"2021","unstructured":"Li Z, Wang F, Li Y, Wang X, Lu Q, Wang D, et al. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis by targeting \u201csubstance P-hepatic stellate cells-hepatocellular carcinoma\u201d axis. Biomaterials. 2021;276:121003.","journal-title":"Biomaterials"},{"key":"1308_CR63","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3390\/cells9092027","volume":"9","author":"L Kaps","year":"2020","unstructured":"Kaps L, Schuppan D. Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells. 2020;9:2027.","journal-title":"Cells"},{"key":"1308_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2240031","volume":"15","author":"J Rajapakse","year":"2023","unstructured":"Rajapakse J, Khatiwada S, Akon AC, Yu KL, Shen S, Zekry A. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions. Gut Microbes. 2023;15:2240031.","journal-title":"Gut Microbes"},{"key":"1308_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","volume":"18","author":"B Ruf","year":"2021","unstructured":"Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112\u201327.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","volume":"16","author":"R Bened\u00e9-Ubieto","year":"2024","unstructured":"Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024;16:2331460.","journal-title":"Gut Microbes"},{"key":"1308_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31312-5","volume":"13","author":"KM Schneider","year":"2022","unstructured":"Schneider KM, Mohs A, Gui W, Galvez EJC, Candels LS, Hoenicke L, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun. 2022;13:3964.","journal-title":"Nat Commun"},{"key":"1308_CR68","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang YX, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70:761\u201374.","journal-title":"Gut"},{"key":"1308_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, et al. D-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv. 2023;9:eadg2697.","journal-title":"Sci Adv"},{"key":"1308_CR70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.32449","volume":"77","author":"C Hu","year":"2023","unstructured":"Hu C, Xu B, Wang X, Wan W, Lu J, Kong D, et al. Gut microbiota\u2013derived short\u2010chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology. 2023;77:48\u201364.","journal-title":"Hepatology"},{"key":"1308_CR71","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song Q, Zhang X, Liu W, Wei H, Liang W, Zhou Y, et al. Bifidobacterium pseudolongum-generated acetate suppresses nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79:1352\u201365.","journal-title":"J Hepatol"},{"key":"1308_CR72","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","volume":"79","author":"E Kotsiliti","year":"2023","unstructured":"Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ, et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signaling. J Hepatol. 2023;79:296\u2013313.","journal-title":"J Hepatol"},{"key":"1308_CR73","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/liv.15466","volume":"43","author":"J Ma","year":"2023","unstructured":"Ma J, Li J, Jin C, Yang J, Zheng C, Chen K, et al. Association of gut microbiome and primary liver cancer: a two-sample Mendelian randomization and case\u2012control study. Liver Int. 2023;43:221\u201333.","journal-title":"Liver Int"},{"key":"1308_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2297846","volume":"16","author":"H Ma","year":"2024","unstructured":"Ma H, Yang L, Liang Y, Liu F, Hu J, Zhang R, et al. B. thetaiotaomicron-derived acetic acid modulate immune microenvironment and tumor growth in hepatocellular carcinoma. Gut Microbes. 2024;16:2297846.","journal-title":"Gut Microbes"},{"key":"1308_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","volume":"74","author":"S Ha","year":"2025","unstructured":"Ha S, Wong VWS, Zhang X, Yu J. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut. 2025;74:141\u201352.","journal-title":"Gut"},{"key":"1308_CR76","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000241","volume":"7","author":"N Ohtani","year":"2023","unstructured":"Ohtani N, Kamiya T, Kawada N. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD\/NASH, HCC, and beyond. Hepatol Commun. 2023;7:e0241.","journal-title":"Hepatol Commun"},{"key":"1308_CR77","doi-asserted-by":"publisher","first-page":"e100007","DOI":"10.1136\/egastro-2023-100007","volume":"1","author":"HCH Lau","year":"2023","unstructured":"Lau HCH, Zhang X, Yu J. Gut microbiota and immune alteration in cancer development: implication for immunotherapy. eGastroenterology. 2023;1:e100007.","journal-title":"eGastroenterology"},{"key":"1308_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167230","volume":"1870","author":"X Liu","year":"2024","unstructured":"Liu X, Li S, Wang L, Ma K. Microecological regulation in HCC therapy: gut microbiome enhances ICI treatment. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167230.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1308_CR79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/HEP.0000000000000047","volume":"78","author":"Y Che","year":"2023","unstructured":"Che Y, Chen G, Guo Q, Duan Y, Feng H, Xia Q. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis. Hepatol Balt Md. 2023;78:88\u2013102.","journal-title":"Hepatol Balt Md"},{"key":"1308_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, et al. Gut microbiota impact on the peripheral immune response in nonalcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12:187.","journal-title":"Nat Commun"},{"key":"1308_CR81","doi-asserted-by":"publisher","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","volume":"10","author":"PC Lee","year":"2022","unstructured":"Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10:e004779.","journal-title":"J Immunother Cancer"},{"key":"1308_CR82","doi-asserted-by":"publisher","first-page":"e008686","DOI":"10.1136\/jitc-2023-008686","volume":"12","author":"C Zhu","year":"2024","unstructured":"Zhu C, Zhang C, Wang S, Xun Z, Zhang D, Lan Z, et al. Characterizations of multikingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. J Immunother Cancer. 2024;12:e008686.","journal-title":"J Immunother Cancer"},{"key":"1308_CR83","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2119055","volume":"14","author":"Z Li","year":"2022","unstructured":"Li Z, Zhang Y, Hong W, Wang B, Chen Y, Yang P, et al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. Gut Microbes. 2022;14:2119055.","journal-title":"Gut Microbes"},{"key":"1308_CR84","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.cmet.2025.01.011","volume":"37","author":"H Wei","year":"2025","unstructured":"Wei H, Suo C, Gu X, Shen S, Lin K, Zhu C, et al. AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. Cell Metab. 2025;37:1103\u20131118.e7.","journal-title":"Cell Metab"},{"key":"1308_CR85","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2486519","volume":"17","author":"M Huang","year":"2025","unstructured":"Huang M, Ji Q, Huang H, Wang X, Wang L. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes. 2025;17:2486519.","journal-title":"Gut Microbes"},{"key":"1308_CR86","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tem.2024.06.003","volume":"35","author":"J Yu","year":"2024","unstructured":"Yu J, Chen X, Yang X, Zhang B. Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment. Trends Endocrinol Metab TEM. 2024;35:1006\u201320.","journal-title":"Trends Endocrinol Metab TEM"},{"key":"1308_CR87","doi-asserted-by":"publisher","first-page":"e100024","DOI":"10.1136\/egastro-2023-100024","volume":"1","author":"RM Rodrigues","year":"2023","unstructured":"Rodrigues RM, Boeckmans J, Vanhaecke T. Macrophages clear out necrotic liver lesions: a new magic trick revealed. eGastroenterology. 2023;1:e100024.","journal-title":"eGastroenterology"},{"key":"1308_CR88","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/cmi.2016.3","volume":"13","author":"MW Robinson","year":"2016","unstructured":"Robinson MW, Harmon C, O\u2019Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13:267\u201376.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR89","doi-asserted-by":"publisher","first-page":"e000003","DOI":"10.1136\/egastro-2023-000003","volume":"1","author":"A Guillot","year":"2023","unstructured":"Guillot A, Tacke F. Spatial dimension of macrophage heterogeneity in liver diseases. eGastroenterology. 2023;1:e000003.","journal-title":"eGastroenterology"},{"key":"1308_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04716-0","volume":"21","author":"J Huang","year":"2023","unstructured":"Huang J, Wu Q, Geller DA, Yan Y. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC). J Transl Med. 2023;21:815.","journal-title":"J Transl Med"},{"key":"1308_CR91","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207.","journal-title":"Signal Transduct Target Ther"},{"key":"1308_CR92","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cac2.12345","volume":"42","author":"K Cheng","year":"2022","unstructured":"Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor\u2010associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42:1112\u201340.","journal-title":"Cancer Commun"},{"key":"1308_CR93","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.7150\/ijbs.70149","volume":"18","author":"Y You","year":"2022","unstructured":"You Y, Wen D, Zeng L, Lu J, Xiao X, Chen Y, et al. ALKBH5\/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression. Int J Biol Sci. 2022;18:5001\u201318.","journal-title":"Int J Biol Sci"},{"key":"1308_CR94","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.gastro.2024.02.025","volume":"167","author":"J Chen","year":"2024","unstructured":"Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, et al. TGF-\u03b21-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12. Gastroenterology. 2024;167:264\u201380.","journal-title":"Gastroenterology"},{"key":"1308_CR95","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.immuni.2021.04.027","volume":"54","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhangyuan G, Wang F, Jin K, Shen H, Zhang L, et al. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity. 2021;54:1168\u20131185.e8.","journal-title":"Immunity"},{"key":"1308_CR96","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41423-024-01199-x","volume":"21","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen W, Qiao S, Zou H, Yu Xjuan, Yang Y, et al. Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20\/CCR6 axis in human hepatocellular carcinoma. Cell Mol Immunol. 2024;21:1120\u201330.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR97","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2024.09.029","volume":"82","author":"X Yang","year":"2025","unstructured":"Yang X, Deng B, Zhao W, Guo Y, Wan Y, Wu Z, et al. FABP5+ lipid-loaded macrophages process tumor-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity. J Hepatol. 2025;82:676\u201389.","journal-title":"J Hepatol"},{"key":"1308_CR98","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","volume":"14","author":"JC Lu","year":"2021","unstructured":"Lu JC, Zhang PF, Huang XY, Guo XJ, Gao C, Zeng HY, et al. Amplification of spatially isolated adenosine pathway by tumor\u2013macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Oncol. 2021;14:200.","journal-title":"J Hematol Oncol"},{"key":"1308_CR99","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","volume":"186","author":"B Ruf","year":"2023","unstructured":"Ruf B, Bruhns M, Babaei S, Kedei N, Ma L, Revsine M, et al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell. 2023;186:3686\u20133705.e32.","journal-title":"Cell"},{"key":"1308_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00872-w","volume":"21","author":"Y Lu","year":"2023","unstructured":"Lu Y, Han G, Zhang Y, Zhang L, Li Z, Wang Q, et al. M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma. Cell Commun Signal. 2023;21:299.","journal-title":"Cell Commun Signal"},{"key":"1308_CR101","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/HEP.0000000000000673","volume":"79","author":"K Li","year":"2024","unstructured":"Li K, Zhang R, Wen F, Zhao Y, Meng F, Li Q, et al. Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC. Hepatology. 2024;79:1293\u2013309.","journal-title":"Hepatology"},{"key":"1308_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102463","volume":"56","author":"X Hao","year":"2022","unstructured":"Hao X, Zheng Z, Liu H, Zhang Y, Kang J, Kong X, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463.","journal-title":"Redox Biol"},{"key":"1308_CR103","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/JLB.3A0318-108R","volume":"105","author":"P Handa","year":"2019","unstructured":"Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, et al. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol. 2019;105:1015\u201326.","journal-title":"J Leukoc Biol"},{"key":"1308_CR104","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-023-02865-0","volume":"42","author":"J Huang","year":"2023","unstructured":"Huang J, Pan H, Sun J, Wu J, Xuan Q, Wang J, et al. TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages. J Exp Clin Cancer Res. 2023;42:286.","journal-title":"J Exp Clin Cancer Res"},{"key":"1308_CR105","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jhep.2023.06.022","volume":"79","author":"Y Lu","year":"2023","unstructured":"Lu Y, Sun Q, Guan Q, Zhang Z, He Q, He J, et al. The XOR-IDH3\u03b1 axis controls macrophage polarization in hepatocellular carcinoma. J Hepatol. 2023;79:1172\u201384.","journal-title":"J Hepatol"},{"key":"1308_CR106","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti\u2010PD\u20101 therapy in hepatocellular carcinoma. Cancer Commun. 2024;44:1231\u201360.","journal-title":"Cancer Commun"},{"key":"1308_CR107","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41418-023-01202-4","volume":"30","author":"S Tan","year":"2023","unstructured":"Tan S, Wang Z, Li N, Guo X, Zhang Y, Ma H, et al. Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response. Cell Death Differ. 2023;30:2104\u201319.","journal-title":"Cell Death Differ"},{"key":"1308_CR108","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jhep.2022.02.019","volume":"77","author":"CY Wei","year":"2022","unstructured":"Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, et al. PKC\u03b1\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022;77:163\u201376.","journal-title":"J Hepatol"},{"key":"1308_CR109","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","volume":"183","author":"A Sharma","year":"2020","unstructured":"Sharma A, Seow JJW, Dutertre CA, Pai R, Bl\u00e9riot C, Mishra A, et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell. 2020;183:377\u2013394.e21.","journal-title":"Cell"},{"key":"1308_CR110","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79:126\u201340.","journal-title":"J Hepatol"},{"key":"1308_CR111","doi-asserted-by":"publisher","first-page":"e005655","DOI":"10.1136\/jitc-2022-005655","volume":"10","author":"G Sun","year":"2022","unstructured":"Sun G, Liu H, Zhao J, Zhang J, Huang T, Sun G, et al. Macrophage GSK3\u03b2-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. J Immunother Cancer. 2022;10:e005655.","journal-title":"J Immunother Cancer"},{"key":"1308_CR112","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, et al. Identification of a tumor immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78:770\u201382.","journal-title":"J Hepatol"},{"key":"1308_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101505","volume":"5","author":"J Ning","year":"2024","unstructured":"Ning J, Ye Y, Shen H, Zhang R, Li H, Song T, et al. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance by generating local immune deprivation. Cell Rep. Med. 2024;5:101505.","journal-title":"Cell Rep. Med"},{"key":"1308_CR114","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-024-00828-8","volume":"5","author":"L Lemaitre","year":"2024","unstructured":"Lemaitre L, Adeniji N, Suresh A, Reguram R, Zhang J, Park J, et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat Cancer. 2024;5:1534\u201356.","journal-title":"Nat Cancer"},{"key":"1308_CR115","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41423-024-01231-0","volume":"21","author":"S Chen","year":"2024","unstructured":"Chen S, Zhang P, Zhu G, Wang B, Cai J, Song L, et al. Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma. Cell Mol Immunol. 2024;21:1505\u201321.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR116","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2022.02.030","volume":"77","author":"R Sun","year":"2022","unstructured":"Sun R, Zhang Z, Bao R, Guo X, Gu Y, Yang W, et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. J Hepatol. 2022;77:453\u201366.","journal-title":"J Hepatol"},{"key":"1308_CR117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, et al. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79:109\u201325.","journal-title":"J Hepatol"},{"key":"1308_CR118","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.molcel.2020.05.004","volume":"78","author":"PP Hou","year":"2020","unstructured":"Hou PP, Luo LJ, Chen HZ, Chen QT, Bian XL, Wu SF, et al. Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment. Mol Cell. 2020;78:1192\u20131206.e10.","journal-title":"Mol Cell"},{"key":"1308_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W, et al. Targeted xCT\u2010mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti\u2010PD\u20101\/L1 response. Adv Sci. 2023;10:2203973.","journal-title":"Adv Sci"},{"key":"1308_CR120","doi-asserted-by":"publisher","first-page":"e004297","DOI":"10.1136\/jitc-2021-004297","volume":"10","author":"Z Yu","year":"2022","unstructured":"Yu Z, Li Y, Li Y, Zhang J, Li M, Ji L, et al. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. J Immunother Cancer. 2022;10:e004297.","journal-title":"J Immunother Cancer"},{"key":"1308_CR121","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/HEP.0000000000000903","volume":"81","author":"X Li","year":"2025","unstructured":"Li X, Zhang Y, Li S, Shi J, Liu C, Li X, et al. Macrophage hitchhiking for systematic suppression in postablative multifocal HCC. Hepatology. 2025;81:44\u201359.","journal-title":"Hepatology"},{"key":"1308_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114560","volume":"161","author":"Z Gao","year":"2023","unstructured":"Gao Z, Feng SR, Chen J, Li X, Shi Y, Tang Z, et al. Inhibition of autophagy in macrophage promotes IL-1\u03b2-mediated hepatocellular carcinoma progression via inflammasome accumulation and self-recruitment. Biomed Pharmacother. 2023;161:114560.","journal-title":"Biomed Pharmacother"},{"key":"1308_CR123","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s43018-024-00824-y","volume":"5","author":"X Qiu","year":"2024","unstructured":"Qiu X, Zhou T, Li S, Wu J, Tang J, Ma G, et al. Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma. Nat Cancer. 2024;5:1557\u201378.","journal-title":"Nat Cancer"},{"key":"1308_CR124","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/hep.32062","volume":"74","author":"Q He","year":"2021","unstructured":"He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, et al. IL\u20101\u03b2\u2010induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up\u2010regulating programmed death ligand 1 and colony\u2010stimulating factor 1. Hepatology. 2021;74:3174\u201393.","journal-title":"Hepatology"},{"key":"1308_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03545-7","volume":"12","author":"G Liu","year":"2021","unstructured":"Liu G, Sun J, Yang ZF, Zhou C, Zhou PY, Guan RY, et al. Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2\/miR-4756\/IFIT1\/3 axis. Cell Death Dis. 2021;12:260.","journal-title":"Cell Death Dis"},{"key":"1308_CR126","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.7150\/thno.41712","volume":"10","author":"Y Dang","year":"2020","unstructured":"Dang Y, Chen J, Feng W, Qiao C, Han W, Nie Y, et al. Interleukin 1\u03b2-mediated HOXC10 overexpression promotes hepatocellular carcinoma metastasis by upregulating PDPK1 and VASP. Theranostics. 2020;10:3833\u201348.","journal-title":"Theranostics"},{"key":"1308_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105233","volume":"161","author":"X Wang","year":"2020","unstructured":"Wang X, Tan Y, Zhang Y, Xu Z, Xu B, Lei H, et al. The novel glycyrrhetinic acid\u2013tetramethylpyrazine conjugate TOGA induces anti-hepatocarcinogenesis by inhibiting the effects of tumor-associated macrophages on tumor cells. Pharm Res. 2020;161:105233.","journal-title":"Pharm Res"},{"key":"1308_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207074","volume":"10","author":"C Xue","year":"2023","unstructured":"Xue C, Gu X, Zheng Q, Shi Q, Yuan X, Chu Q, et al. Effects of 3\u2010HAA on HCC by regulating the heterogeneous macrophages\u2014a scRNA\u2010seq analysis. Adv Sci. 2023;10:2207074.","journal-title":"Adv Sci"},{"key":"1308_CR129","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","volume":"164","author":"C Zhou","year":"2023","unstructured":"Zhou C, Weng J, Liu C, Liu S, Hu Z, Xie X, et al. Disruption of SLFN11 deficiency\u2013induced CCL2 signaling and macrophage M2 polarization potentiates Anti\u2013PD-1 therapy efficacy in hepatocellular carcinoma. Gastroenterology. 2023;164:1261\u201378.","journal-title":"Gastroenterology"},{"key":"1308_CR130","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jhep.2022.03.039","volume":"77","author":"S Chuah","year":"2022","unstructured":"Chuah S, Lee J, Song Y, Kim HD, Wasser M, Kaya NA, et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatol. 2022;77:683\u201394.","journal-title":"J Hepatol"},{"key":"1308_CR131","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","volume":"10","author":"Y Xia","year":"2022","unstructured":"Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. 2022;10:e004656.","journal-title":"J Immunother Cancer"},{"key":"1308_CR132","unstructured":"Yang M, Song X, Zhang F, Li M, Chang W, Wang Z, et al. Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse. Hepatology [Internet]. 2024 Jun 20 [cited 2025 Jan 10]; Available from: https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000979."},{"key":"1308_CR133","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","volume":"184","author":"Y Sun","year":"2021","unstructured":"Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404\u2013421.e16.","journal-title":"Cell"},{"key":"1308_CR134","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2021.09.022","volume":"522","author":"L Pang","year":"2021","unstructured":"Pang L, Ng KTP, Liu J, Yeung WHO, Zhu J, Chiu TLS, et al. Plasmacytoid dendritic cells recruited by HIF-1\u03b1\/eADO\/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Lett. 2021;522:80\u201392.","journal-title":"Cancer Lett"},{"key":"1308_CR135","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/0008-5472.CAN-22-1199","volume":"82","author":"L Pang","year":"2022","unstructured":"Pang L, Yeung OWH, Ng KTP, Liu H, Zhu J, Liu J, et al. Postoperative plasmacytoid dendritic cells secrete IFN\u03b1 to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence. Cancer Res. 2022;82:4206\u201318.","journal-title":"Cancer Res"},{"key":"1308_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.248","volume":"3","author":"Y Jin","year":"2024","unstructured":"Jin Y, Cai S, Zhou Y, Guo D, Zeng Y, Xu W, et al. Targeting SLC7A11\/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti\u2010tumor immune response. iMeta. 2024;3:e248.","journal-title":"iMeta"},{"key":"1308_CR137","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell\u2013CD4+ T helper cell niches enable CD8+ T-cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023;29:1389\u201399.","journal-title":"Nat Med"},{"key":"1308_CR138","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jhep.2022.03.011","volume":"77","author":"S Wang","year":"2022","unstructured":"Wang S, Wu Q, Chen T, Su R, Pan C, Qian J, et al. Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell\u2013NK cell axis in murine hepatocellular carcinoma model. J Hepatol. 2022;77:467\u201378.","journal-title":"J Hepatol"},{"key":"1308_CR139","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/HEP.0000000000000599","volume":"79","author":"S Chen","year":"2024","unstructured":"Chen S, Liao C, Hu H, Liao J, Chen Z, Li S, et al. Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC. Hepatology. 2024;79:780\u201397.","journal-title":"Hepatology"},{"key":"1308_CR140","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jconrel.2024.01.048","volume":"369","author":"F Ao","year":"2024","unstructured":"Ao F, Li X, Tan Y, Jiang Z, Yang F, Guo J, et al. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment. J Control Release. 2024;369:296\u2013308.","journal-title":"J Control Release"},{"key":"1308_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100324","volume":"3","author":"R Chen","year":"2021","unstructured":"Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signaling in liver diseases. JHEP Rep. 2021;3:100324.","journal-title":"JHEP Rep"},{"key":"1308_CR142","doi-asserted-by":"publisher","first-page":"e010157","DOI":"10.1136\/jitc-2024-010157","volume":"12","author":"J Cao","year":"2024","unstructured":"Cao J, Su B, Zhang C, Peng R, Tu D, Deng Q, et al. Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma. J Immunother Cancer. 2024;12:e010157.","journal-title":"J Immunother Cancer"},{"key":"1308_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308009","volume":"11","author":"W Hong","year":"2024","unstructured":"Hong W, Zhang Y, Wang S, Li Z, Zheng D, Hsu S, et al. RECQL4 inhibits radiation\u2010induced tumor immune awakening via Suppressing the cGAS\u2010STING pathway in hepatocellular carcinoma. Adv Sci. 2024;11:2308009.","journal-title":"Adv Sci"},{"key":"1308_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02354-2","volume":"22","author":"Q Du","year":"2024","unstructured":"Du Q, Luo Y, Xu L, Du C, Zhang W, Xu J, et al. Smart responsive Fe\/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation. J Nanobiotechnology. 2024;22:95.","journal-title":"J Nanobiotechnology"},{"key":"1308_CR145","first-page":"57","volume":"21","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Li T, Zheng X, Lin L, Wang X, Li B, et al. Nanodrug enhances postablation immunotherapy of hepatocellular carcinoma by promoting dendritic cell maturation and antigen presentation. Bioact Mater. 2023;21:57\u201368.","journal-title":"Bioact Mater"},{"key":"1308_CR146","doi-asserted-by":"crossref","unstructured":"Morita S, Lei PJ, Shigeta K, Ando T, Kobayashi T, Kikuchi H, et al. Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma. Cancer Immunol Res [Internet]. 2024 Nov 8 [cited 2025 Jan 10]; Available from: https:\/\/aacrjournals.org\/cancerimmunolres\/article\/doi\/10.1158\/2326-6066.CIR-24-0324\/749959\/Combination-CXCR4-and-PD1-blockade-enhances.","DOI":"10.1158\/2326-6066.CIR-24-0324"},{"key":"1308_CR147","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-022-01266-8","volume":"15","author":"B Zuo","year":"2022","unstructured":"Zuo B, Zhang Y, Zhao K, Wu L, Qi H, Yang R, et al. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. J Hematol Oncol. 2022;15:46.","journal-title":"J Hematol Oncol"},{"key":"1308_CR148","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jconrel.2024.10.069","volume":"376","author":"T Li","year":"2024","unstructured":"Li T, Li B, Lin L, Chen G, Wang X, Chen Y, et al. Anti-CTLA-4 antibody self-presented dendritic cell nanovesicles boost the immunotherapy of hepatocellular carcinoma after microwave ablation. J Control Release. 2024;376:913\u201329.","journal-title":"J Control Release"},{"key":"1308_CR149","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","volume":"10","author":"S Peng","year":"2022","unstructured":"Peng S, Chen S, Hu W, Mei J, Zeng X, Su T, et al. Combination neoantigen-based dendritic cell vaccination and adoptive t-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res. 2022;10:728\u201344.","journal-title":"Cancer Immunol Res"},{"key":"1308_CR150","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2021.09.011","volume":"522","author":"H Chen","year":"2021","unstructured":"Chen H, Zhou XH, Li JR, Zheng TH, Yao FB, Gao B, et al. Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett. 2021;522:22\u201331.","journal-title":"Cancer Lett"},{"key":"1308_CR151","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","volume":"19","author":"D Geh","year":"2022","unstructured":"Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19:257\u201373.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1308_CR152","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230527","volume":"309","author":"H Jiang","year":"2023","unstructured":"Jiang H, Yang C, Chen Y, Wang Y, Wu Y, Chen W, et al. Development of a model including MRI features for predicting advanced-stage recurrence of hepatocellular carcinoma after liver resection. Radiology. 2023;309:e230527.","journal-title":"Radiology"},{"key":"1308_CR153","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1007\/s00259-020-05186-y","volume":"48","author":"X Li","year":"2021","unstructured":"Li X, Montazeri SA, Paz-Fumagalli R, Padula CA, Wang W, Mody K, et al. Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres. Eur J Nucl Med Mol Imaging. 2021;48:2624\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1308_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100995","volume":"6","author":"O \u00d6cal","year":"2024","unstructured":"\u00d6cal O, Kimm MA, Hoang TPT, Pech M, \u00d6cal E, Ben Khaled N, et al. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization. JHEP Rep. 2024;6:100995.","journal-title":"JHEP Rep"},{"key":"1308_CR155","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","volume":"17","author":"M Metzemaekers","year":"2020","unstructured":"Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. Cell Mol Immunol. 2020;17:433\u201350. May","journal-title":"Cell Mol Immunol"},{"key":"1308_CR156","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241442","volume":"222","author":"JMN Teo","year":"2025","unstructured":"Teo JMN, Chen Z, Chen W, Tan RJY, Cao Q, Chu Y, et al. Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma. J Exp Med. 2025;222:e20241442.","journal-title":"J Exp Med"},{"key":"1308_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37361-8","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z, Soni N, Pinero G, Giotti B, Eddins DJ, Lindblad KE, et al. Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. Nat Commun. 2023;14:1839.","journal-title":"Nat Commun"},{"key":"1308_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102297","volume":"97","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yu S, Lv C, Tian Y. NETosis in tumor microenvironment of liver: from primary to metastatic hepatic carcinoma. Aging Res Rev. 2024;97:102297.","journal-title":"Aging Res Rev"},{"key":"1308_CR159","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/hep.29914","volume":"68","author":"DJ Van Der Windt","year":"2018","unstructured":"Van Der Windt DJ, Sud V, Zhang H, Varley PR, Goswami J, Yazdani HO, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2018;68:1347\u201360.","journal-title":"Hepatology"},{"key":"1308_CR160","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-019-0836-0","volume":"13","author":"LY Yang","year":"2020","unstructured":"Yang LY, Luo Q, Lu L, Zhu WW, Sun HT, Wei R, et al. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma by provoking tumorous inflammatory response. J Hematol Oncol. 2020;13:3.","journal-title":"J Hematol Oncol"},{"key":"1308_CR161","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/cac2.12388","volume":"43","author":"X Zhan","year":"2023","unstructured":"Zhan X, Wu R, Kong X, You Y, He K, Sun X, et al. Elevated neutrophil extracellular traps by HBV\u2010mediated S100A9\u2010TLR4\/RAGE\u2010ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma. Cancer Commun. 2023;43:225\u201345.","journal-title":"Cancer Commun"},{"key":"1308_CR162","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jhep.2021.07.032","volume":"75","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang H, Wang Y, Brown ZJ, Xia Y, Huang Z, et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in nonalcoholic steatohepatitis. J Hepatol. 2021;75:1271\u201383.","journal-title":"J Hepatol"},{"key":"1308_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217098","volume":"598","author":"Y Yu","year":"2024","unstructured":"Yu Y, Zhang C, Dong B, Zhang Z, Li X, Huang S, et al. Neutrophil extracellular traps promote immune escape in hepatocellular carcinoma by upregulating CD73 through Notch2. Cancer Lett. 2024;598:217098.","journal-title":"Cancer Lett"},{"key":"1308_CR164","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40164-024-00476-9","volume":"13","author":"XT Shen","year":"2024","unstructured":"Shen XT, Xie SZ, Zheng X, Zou TT, Hu BY, Xu J, et al. Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma. Exp Hematol Oncol. 2024;13:20.","journal-title":"Exp Hematol Oncol"},{"key":"1308_CR165","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1158\/0008-5472.CAN-23-2986","volume":"84","author":"M Song","year":"2024","unstructured":"Song M, Zhang C, Cheng S, Ouyang D, Ping Y, Yang J, et al. DNA of neutrophil extracellular traps binds TMCO6 to impair CD8+ T-cell immunity in hepatocellular carcinoma. Cancer Res. 2024;84:1613\u201329.","journal-title":"Cancer Res"},{"key":"1308_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37227-z","volume":"14","author":"T Wang","year":"2023","unstructured":"Wang T, Zhou Y, Zhou Z, Zhang P, Yan R, Sun L, et al. Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps. Nat Commun. 2023;14:1513.","journal-title":"Nat Commun"},{"key":"1308_CR167","doi-asserted-by":"publisher","first-page":"e009642","DOI":"10.1136\/jitc-2024-009642","volume":"12","author":"X Zheng","year":"2024","unstructured":"Zheng X, Yang L, Shen X, Pan J, Chen Y, Chen J, et al. Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2024;12:e009642.","journal-title":"J Immunother Cancer"},{"key":"1308_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1134521","volume":"14","author":"H Xin","year":"2023","unstructured":"Xin H, Lai Q, Zhou Y, He J, Song Y, Liao M, et al. Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma. Front Immunol. 2023;14:1134521.","journal-title":"Front Immunol"},{"key":"1308_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216903","volume":"592","author":"JJ Pan","year":"2024","unstructured":"Pan JJ, Xie SZ, Zheng X, Xu JF, Xu H, Yin RQ, et al. Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis by enhancing CXCL1-dependent infiltration of tumor-associated neutrophils. Cancer Lett. 2024;592:216903.","journal-title":"Cancer Lett"},{"key":"1308_CR170","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.ccell.2024.10.008","volume":"42","author":"C Yang","year":"2024","unstructured":"Yang C, Geng H, Yang X, Ji S, Liu Z, Feng H, et al. Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer Cell. 2024;42:2064\u20132081.e19.","journal-title":"Cancer Cell"},{"key":"1308_CR171","doi-asserted-by":"publisher","first-page":"e100166","DOI":"10.1136\/egastro-2024-100166","volume":"2","author":"Y Guan","year":"2024","unstructured":"Guan Y, Feng D, Maccioni L, Wang Y, Gao B. New therapeutic target for alcohol-associated hepatitis (AH): AH-associated IL-8+ neutrophils. eGastroenterology. 2024;2:e100166.","journal-title":"eGastroenterology"},{"key":"1308_CR172","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178616","volume":"134","author":"Y Guan","year":"2024","unstructured":"Guan Y, Peiffer B, Feng D, Parra MA, Wang Y, Fu Y, et al. IL-8+ neutrophils drive inexorable inflammation in severe alcohol-associated hepatitis. J Clin Investig. 2024;134:e178616.","journal-title":"J Clin Investig"},{"key":"1308_CR173","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/hep.31855","volume":"74","author":"X Xu","year":"2021","unstructured":"Xu X, Ye L, Zhang Q, Shen H, Li S, Zhang X, et al. Group\u20102 innate lymphoid cells promote HCC progression through CXCL2\u2010neutrophil\u2010induced immunosuppression. Hepatology. 2021;74:2526\u201343.","journal-title":"Hepatology"},{"key":"1308_CR174","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022;71:2093\u2013106.","journal-title":"Gut"},{"key":"1308_CR175","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40164-024-00571-x","volume":"13","author":"SZ Xie","year":"2024","unstructured":"Xie SZ, Yang LY, Wei R, Shen XT, Pan JJ, Yu SZ, et al. Targeting SPP1-orchestrated neutrophil extracellular traps-dominant premetastatic niche reduced HCC lung metastasis. Exp Hematol Oncol. 2024;13:111.","journal-title":"Exp Hematol Oncol"},{"key":"1308_CR176","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jhep.2023.08.024","volume":"79","author":"Y Meng","year":"2023","unstructured":"Meng Y, Ye F, Nie P, Zhao Q, An L, Wang W, et al. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. J Hepatol. 2023;79:1435\u201349.","journal-title":"J Hepatol"},{"key":"1308_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46118-w","volume":"15","author":"M He","year":"2024","unstructured":"He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, et al. Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma. Nat Commun. 2024;15:1754.","journal-title":"Nat Commun"},{"key":"1308_CR178","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","volume":"81","author":"P Xie","year":"2024","unstructured":"Xie P, Yu M, Zhang B, Yu Q, Zhao Y, Wu M, et al. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. J Hepatol. 2024;81:93\u2013107.","journal-title":"J Hepatol"},{"key":"1308_CR179","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","volume":"28","author":"R Esteban-Fabr\u00f3","year":"2022","unstructured":"Esteban-Fabr\u00f3 R, Willoughby CE, Piqu\u00e9-Gili M, Montironi C, Abril-Fornaguera J, Peix J, et al. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma. Clin Cancer Res. 2022;28:2449\u201360.","journal-title":"Clin Cancer Res"},{"key":"1308_CR180","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105631","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, et al. Remodeling tumor\u2010associated neutrophils to enhance dendritic cell\u2010based HCC neoantigen nano\u2010vaccine efficiency. Adv Sci. 2022;9:2105631.","journal-title":"Adv Sci"},{"key":"1308_CR181","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","volume":"135","author":"B Hoechst","year":"2008","unstructured":"Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kr\u00fcger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology. 2008;135:234\u201343.","journal-title":"Gastroenterology"},{"key":"1308_CR182","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","volume":"50","author":"B Hoechst","year":"2009","unstructured":"Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50:799\u2013807.","journal-title":"Hepatology"},{"key":"1308_CR183","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity. 2021;54:875\u201384.","journal-title":"Immunity"},{"key":"1308_CR184","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/hep.30676","volume":"70","author":"Y Li","year":"2019","unstructured":"Li Y, Liu Z, Wang J, Yu J, Li Z, Yang H, et al. Receptor\u2010interacting protein kinase 3 deficiency recruits myeloid\u2010derived suppressor cells to hepatocellular carcinoma through the chemokine (C\u2010X\u2010C Motif) ligand 1\u2013chemokine (C\u2010X\u2010C Motif) receptor 2 axis. Hepatology. 2019;70:1564\u201381.","journal-title":"Hepatology"},{"key":"1308_CR185","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.3390\/ijms20205079","volume":"20","author":"CC Hsieh","year":"2019","unstructured":"Hsieh CC, Hung CH, Chiang M, Tsai YC, He JT. Hepatic stellate cells enhance liver cancer progression by inducing myeloid-derived suppressor cells through interleukin-6 signaling. Int J Mol Sci. 2019;20:5079.","journal-title":"Int J Mol Sci"},{"key":"1308_CR186","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms21218412","volume":"21","author":"J Korbecki","year":"2020","unstructured":"Korbecki J, Kojder K, Simi\u0144ska D, Bohatyrewicz R, Gutowska I, Chlubek D, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020;21:8412.","journal-title":"Int J Mol Sci"},{"key":"1308_CR187","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1158\/2326-6066.CIR-14-0182","volume":"3","author":"J Medina-Echeverz","year":"2015","unstructured":"Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, et al. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol Res. 2015;3:557\u201366.","journal-title":"Cancer Immunol Res"},{"key":"1308_CR188","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.7150\/thno.57659","volume":"11","author":"Q He","year":"2021","unstructured":"He Q, Huang W, Liu D, Zhang T, Wang Y, Ji X, et al. Homeobox B5 promotes metastasis and poor prognosis in hepatocellular carcinoma, via FGFR4 and CXCL1 upregulation. Theranostics. 2021;11:5759\u201377.","journal-title":"Theranostics"},{"key":"1308_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1217400","volume":"14","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Wu D, Li J, Huang D, Zhao Y, Gao T, et al. Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma. Front Pharm. 2023;14:1217400.","journal-title":"Front Pharm"},{"key":"1308_CR190","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/hep.27867","volume":"62","author":"S Wan","year":"2015","unstructured":"Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015;62:1304\u201312.","journal-title":"Hepatology"},{"key":"1308_CR191","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/cells12101406","volume":"12","author":"J Korbecki","year":"2023","unstructured":"Korbecki J, Bosiacki M, Barczak K, \u0141agocka R, Chlubek D, Baranowska-Bosiacka I. The clinical significance and role of CXCL1 Chemokine in Gastrointestinal Cancers. Cells. 2023;12:1406.","journal-title":"Cells"},{"key":"1308_CR192","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00262-015-1736-y","volume":"64","author":"J Medina-Echeverz","year":"2015","unstructured":"Medina-Echeverz J, Eggert T, Han M, Greten TF. Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunol Immunother. 2015;64:931\u201340.","journal-title":"Cancer Immunol Immunother"},{"key":"1308_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06542-8","volume":"15","author":"H Wang","year":"2024","unstructured":"Wang H, Zhou Q, Xie DF, Xu Q, Yang T, Wang W. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy. Cell Death Dis. 2024;15:165.","journal-title":"Cell Death Dis"},{"key":"1308_CR194","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41416-019-0639-7","volume":"122","author":"G Meng","year":"2020","unstructured":"Meng G, Li B, Chen A, Zheng M, Xu T, Zhang H, et al. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma. Br J Cancer. 2020;122:111\u201320.","journal-title":"Br J Cancer"},{"key":"1308_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113835","volume":"43","author":"Y Mei","year":"2024","unstructured":"Mei Y, Zhu Y, Yong KSM, Hanafi ZB, Gong H, Liu Y, et al. IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. Cell Rep. 2024;43:113835. Mar","journal-title":"Cell Rep"},{"key":"1308_CR196","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hep.30134","volume":"69","author":"L Liu","year":"2019","unstructured":"Liu L, Zhang Z, Zheng B, Shi Y, Duan M, Ma L, et al. CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma. Hepatology. 2019;69:143\u201359.","journal-title":"Hepatology"},{"key":"1308_CR197","doi-asserted-by":"crossref","unstructured":"Wen J, Zhang X, Wong CC, Zhang Y, Pan Y, Zhou Y, et al. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma. Gut. 2024;73:2023\u201336.","DOI":"10.1136\/gutjnl-2023-331117"},{"key":"1308_CR198","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41:1294\u20131308.e8.","journal-title":"Cancer Cell"},{"key":"1308_CR199","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jhep.2023.06.021","volume":"79","author":"L Wang","year":"2023","unstructured":"Wang L, Zhu L, Liang C, Huang X, Liu Z, Huo J, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol. 2023;79:1185\u2013200.","journal-title":"J Hepatol"},{"key":"1308_CR200","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1824863","volume":"9","author":"SG Kalathil","year":"2020","unstructured":"Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y. Tivozanib mediated inhibition of c-Kit\/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. OncoImmunology. 2020;9:1824863.","journal-title":"OncoImmunology"},{"key":"1308_CR201","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/gutjnl-2022-327909","volume":"72","author":"C Conche","year":"2023","unstructured":"Conche C, Finkelmeier F, Pe\u0161i\u0107 M, Nicolas AM, B\u00f6ttger TW, Kennel KB, et al. Combining ferroptosis induction with MDSC blockade renders primary tumors and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023;72:1774\u201382.","journal-title":"Gut"},{"key":"1308_CR202","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/gutjnl-2018-317257","volume":"69","author":"M Liu","year":"2020","unstructured":"Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2020;69:365\u201379.","journal-title":"Gut"},{"key":"1308_CR203","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","volume":"20","author":"DI Godfrey","year":"2019","unstructured":"Godfrey DI, Koay HF, McCluskey J, Gherardin NA. The biology and functional importance of MAIT cells. Nat Immunol. 2019;20:1110\u201328.","journal-title":"Nat Immunol"},{"key":"1308_CR204","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3389\/fimmu.2020.01014","volume":"11","author":"TSC Hinks","year":"2020","unstructured":"Hinks TSC, Zhang XW. MAIT cell activation and functions. Front Immunol. 2020;11:1014.","journal-title":"Front Immunol"},{"key":"1308_CR205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369236","volume":"15","author":"M Yigit","year":"2024","unstructured":"Yigit M, Basoglu OF, Unutmaz D. Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential. Front Immunol. 2024;15:1369236.","journal-title":"Front Immunol"},{"key":"1308_CR206","doi-asserted-by":"publisher","first-page":"e003685","DOI":"10.1136\/jitc-2021-003685","volume":"9","author":"W Huang","year":"2021","unstructured":"Huang W, Ye D, He W, He X, Shi X, Gao Y. Activated but impaired IFN-\u03b3 production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma. J Immunother Cancer. 2021;9:e003685. Nov","journal-title":"J Immunother Cancer"},{"key":"1308_CR207","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1158\/1078-0432.CCR-18-3040","volume":"25","author":"M Duan","year":"2019","unstructured":"Duan M, Goswami S, Shi JY, Wu LJ, Wang XY, Ma JQ, et al. Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin Cancer Res. 2019;25:3304\u201316.","journal-title":"Clin Cancer Res"},{"key":"1308_CR208","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3389\/fimmu.2018.01602","volume":"9","author":"J Dias","year":"2018","unstructured":"Dias J, Boulouis C, Sobkowiak MJ, Lal KG, Emg\u00e5rd J, Buggert M, et al. Factors influencing functional heterogeneity in human mucosa-associated invariant T cells. Front Immunol. 2018;9:1602.","journal-title":"Front Immunol"},{"key":"1308_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609900","volume":"11","author":"F Zeng","year":"2021","unstructured":"Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Predicting non-alcoholic fatty liver disease progression and immune deregulations by specific gene expression patterns. Front Immunol. 2021;11:609900.","journal-title":"Front Immunol"},{"key":"1308_CR210","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342\u20131356.e16.","journal-title":"Cell"},{"key":"1308_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109770","volume":"256","author":"C Zhou","year":"2023","unstructured":"Zhou C, Sun BY, Zhou Pyun, Yang ZF, Wang ZT, Liu G, et al. MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway. Clin Immunol. 2023;256:109770.","journal-title":"Clin Immunol"},{"key":"1308_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04450-y","volume":"9","author":"P Hegde","year":"2018","unstructured":"Hegde P, Weiss E, Paradis V, Wan J, Mabire M, Sukriti S, et al. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nat Commun. 2018;9:2146.","journal-title":"Nat Commun"},{"key":"1308_CR213","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/HEP.0000000000000014","volume":"78","author":"S Fu","year":"2023","unstructured":"Fu S, Liu M, Zhu C, Zhang H, Zhao C, Xie Y, et al. Regulatory mucosa-associated invariant T cells controlled by \u03b21 adrenergic receptor signaling contribute to hepatocellular carcinoma progression. Hepatology. 2023;78:72\u201387.","journal-title":"Hepatology"},{"key":"1308_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100318","volume":"3","author":"K Healy","year":"2021","unstructured":"Healy K, Pavesi A, Parrot T, Sobkowiak MJ, Reinsbach SE, Davanian H, et al. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate toward HBV-HCC while retaining antimicrobial functions. JHEP Rep. 2021;3:100318.","journal-title":"JHEP Rep"},{"key":"1308_CR215","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/cells10061369","volume":"10","author":"C Rennert","year":"2021","unstructured":"Rennert C, Tauber C, Fehrenbach P, Heim K, Bettinger D, Sogukpinar \u00d6, et al. Adaptive subsets limit the anti-tumoral NK-cell activity in hepatocellular carcinoma. Cells. 2021;10:1369.","journal-title":"Cells"},{"key":"1308_CR216","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/cells10030614","volume":"10","author":"A Zecca","year":"2021","unstructured":"Zecca A, Barili V, Rizzo D, Olivani A, Biasini E, Laccabue D, et al. Intratumor regulatory noncytotoxic NK Cells in patients with hepatocellular carcinoma. Cells. 2021;10:614.","journal-title":"Cells"},{"key":"1308_CR217","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3390\/cells10061495","volume":"10","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Yoshio S, Yamazoe T, Mori T, Tsustui Y, Kawai H, et al. Phenotypic characterization by single-cell mass cytometry of human intrahepatic and peripheral NK cells in patients with hepatocellular carcinoma. Cells. 2021;10:1495.","journal-title":"Cells"},{"key":"1308_CR218","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/HEP.0000000000000804","volume":"80","author":"SA Engelskircher","year":"2024","unstructured":"Engelskircher SA, Chen PC, Strunz B, Oltmanns C, Ristic T, Owusu Sekyere S, et al. Impending HCC diagnosis in patients with cirrhosis after HCV cure features a natural killer cell signature. Hepatology. 2024;80:202\u201322.","journal-title":"Hepatology"},{"key":"1308_CR219","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31:1327\u20131343.e5.","journal-title":"Cell Stem Cell"},{"key":"1308_CR220","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1053\/j.gastro.2020.01.028","volume":"158","author":"WH Qin","year":"2020","unstructured":"Qin WH, Yang ZS, Li M, Chen Y, Zhao XF, Qin YY, et al. High serum levels of cholesterol increase antitumor functions of nature killer cells and reduce growth of liver tumors in mice. Gastroenterology. 2020;158:1713\u201327.","journal-title":"Gastroenterology"},{"key":"1308_CR221","doi-asserted-by":"crossref","unstructured":"Cui Z, Li H, Liu C, Wang J, Chen C, Hu S, et al. Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T-cell subpopulations in hepatocellular carcinoma. Aging [Internet]. 2024 Apr 5 [cited 2025 Jan 4]; Available from: https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205723.","DOI":"10.18632\/aging.205723"},{"key":"1308_CR222","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.13611","volume":"169","author":"W Yu","year":"2023","unstructured":"Yu W, He J, Wang F, He Q, Shi Y, Tao X, et al. NR4A1 mediates NK \u2010cell dysfunction in hepatocellular carcinoma via the IFN \u2010\u03b3\/p\u2010STAT1\/IRF1 pathway. Immunology. 2023;169:69\u201382.","journal-title":"Immunology"},{"key":"1308_CR223","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00018-021-04051-x","volume":"79","author":"H Sun","year":"2022","unstructured":"Sun H, Kim E, Ryu J, Lee H, Shin EA, Lee M, et al. TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes. Cell Mol Life Sci. 2022;79:49.","journal-title":"Cell Mol Life Sci"},{"key":"1308_CR224","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1016\/j.apsb.2023.04.010","volume":"13","author":"P Shen","year":"2023","unstructured":"Shen P, Jia Y, Zhou W, Zheng W, Wu Y, Qu S, et al. A biomimetic liver cancer on-a-chip reveals a critical role of LIPOCALIN-2 in promoting hepatocellular carcinoma progression. Acta Pharm Sin B. 2023;13:4621\u201337.","journal-title":"Acta Pharm Sin B"},{"key":"1308_CR225","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1172\/JCI81136","volume":"126","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Investig. 2016;126:1216\u201323.","journal-title":"J Clin Investig"},{"key":"1308_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01222-5","volume":"19","author":"PF Zhang","year":"2020","unstructured":"Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, Shi GM, et al. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer. 2020;19:110.","journal-title":"Mol Cancer"},{"key":"1308_CR227","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/gutjnl-2021-325288","volume":"71","author":"B Heinrich","year":"2022","unstructured":"Heinrich B, Gertz EM, Sch\u00e4ffer AA, Craig A, Ruf B, Subramanyam V, et al. The tumor microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut. 2022;71:1161\u201375.","journal-title":"Gut"},{"key":"1308_CR228","doi-asserted-by":"publisher","first-page":"e000301","DOI":"10.1136\/jitc-2019-000301","volume":"8","author":"DJ Park","year":"2020","unstructured":"Park DJ, Sung PS, Kim JH, Lee GW, Jang JW, Jung ES, et al. EpCAM-high liver cancer stem cells resist natural killer cell\u2013mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8:e000301.","journal-title":"J Immunother Cancer"},{"key":"1308_CR229","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05724-4","volume":"22","author":"X Lin","year":"2024","unstructured":"Lin X, Liu Z, Dong X, Wang K, Sun Y, Zhang H, et al. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. J Transl Med. 2024;22:929.","journal-title":"J Transl Med"},{"key":"1308_CR230","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/imm.13677","volume":"170","author":"D Wu","year":"2023","unstructured":"Wu D, Li Y. Application of adoptive cell therapy in hepatocellular carcinoma. Immunology. 2023;170:453\u201369.","journal-title":"Immunology"},{"key":"1308_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04873-w","volume":"22","author":"G Yu","year":"2024","unstructured":"Yu G, Zhang Z, Eresen A, Hou Q, Garcia EE, Yu Z, et al. MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma. J Transl Med. 2024;22:76.","journal-title":"J Transl Med"},{"key":"1308_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121506","volume":"284","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Gong Y, Chen X, Zhang Q, Zhang X, He Y, et al. Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents postresection recurrence of hepatocellular carcinoma. Biomaterials. 2022;284:121506.","journal-title":"Biomaterials"},{"key":"1308_CR233","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jhep.2024.01.028","volume":"80","author":"R Xiao","year":"2024","unstructured":"Xiao R, Tian Y, Zhang J, Li N, Qi M, Liu L, et al. Increased Siglec-9\/Siglec-9 L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy. J Hepatol. 2024;80:792\u2013804.","journal-title":"J Hepatol"},{"key":"1308_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216909","volume":"592","author":"X Shi","year":"2024","unstructured":"Shi X, Chen W, Yin Y, Cao H, Wang X, Jiang W, et al. RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis. Cancer Lett. 2024;592:216909.","journal-title":"Cancer Lett"},{"key":"1308_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215880","volume":"547","author":"X Wang","year":"2022","unstructured":"Wang X, Hu R, Song Z, Zhao H, Pan Z, Feng Y, et al. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. Cancer Lett. 2022;547:215880.","journal-title":"Cancer Lett"},{"key":"1308_CR236","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/hep.32658","volume":"78","author":"X Guo","year":"2023","unstructured":"Guo X, Tan S, Wang T, Sun R, Li S, Tian P, et al. NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. Hepatology. 2023;78:468\u201385.","journal-title":"Hepatology"},{"key":"1308_CR237","doi-asserted-by":"crossref","unstructured":"Sun Y, Li T, Ding L, Wang J, Chen C, Liu T, et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology [Internet]. 2024 May 23 [cited 2025 Jan 4]; Available from: https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000934.","DOI":"10.1097\/HEP.0000000000000934"},{"key":"1308_CR238","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1016\/j.ymthe.2024.09.025","volume":"32","author":"WN Liu","year":"2024","unstructured":"Liu WN, Harden SL, Tan SLW, Tan RJR, Fong SY, Tan SY, et al. Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT cotargeting. Mol Ther. 2024;32:3895\u2013914.","journal-title":"Mol Ther"},{"key":"1308_CR239","doi-asserted-by":"publisher","first-page":"e006817","DOI":"10.1136\/jitc-2023-006817","volume":"11","author":"B Pan","year":"2023","unstructured":"Pan B, Chen Z, Zhang X, Wang Z, Yao Y, Wu X, et al. 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis. J Immunother Cancer. 2023;11:e006817.","journal-title":"J Immunother Cancer"},{"key":"1308_CR240","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156774","volume":"132","author":"S Salman","year":"2022","unstructured":"Salman S, Meyers DJ, Wicks EE, Lee SN, Datan E, Thomas AM, et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. J Clin Investig. 2022;132:e156774.","journal-title":"J Clin Investig"},{"key":"1308_CR241","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/cells12070996","volume":"12","author":"A Arulanandam","year":"2023","unstructured":"Arulanandam A, Lin L, Chang HM, Cerutti M, Choblet S, Gao P, et al. Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3. Cells. 2023;12:996.","journal-title":"Cells"},{"key":"1308_CR242","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1038\/s41388-021-01880-9","volume":"40","author":"X Liu","year":"2021","unstructured":"Liu X, Li L, Si F, Huang L, Zhao Y, Zhang C, et al. NK and NKT cells have distinct properties and functions in cancer. Oncogene. 2021;40:4521\u201337.","journal-title":"Oncogene"},{"key":"1308_CR243","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41423-022-00872-3","volume":"19","author":"W Tang","year":"2022","unstructured":"Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T-cell dysfunction in obese liver. Cell Mol Immunol. 2022;19:834\u201347.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110454","volume":"38","author":"F Mirshahi","year":"2022","unstructured":"Mirshahi F, Aqbi HF, Isbell M, Manjili SH, Guo C, Saneshaw M, et al. Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. Cell Rep. 2022;38:110454.","journal-title":"Cell Rep"},{"key":"1308_CR245","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2002068","volume":"10","author":"L Tao","year":"2021","unstructured":"Tao L, Wang S, Kang G, Jiang S, Yin W, Zong L, et al. PD-1 blockade improves the anti-tumor potency of exhausted CD3+ CD56+ NKT-like cells in patients with primary hepatocellular carcinoma. OncoImmunology. 2021;10:2002068.","journal-title":"OncoImmunology"},{"key":"1308_CR246","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2021.03.002","volume":"506","author":"Y Yan","year":"2021","unstructured":"Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y, et al. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10\/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 2021;506:95\u2013106.","journal-title":"Cancer Lett"},{"key":"1308_CR247","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41423-022-00901-1","volume":"19","author":"S Curio","year":"2022","unstructured":"Curio S, Belz GT. The unique role of innate lymphoid cells in cancer and the hepatic microenvironment. Cell Mol Immunol. 2022;19:1012\u201329.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR248","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/hep.32444","volume":"76","author":"Y He","year":"2022","unstructured":"He Y, Luo J, Zhang G, Jin Y, Wang N, Lu J, et al. Single\u2010cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma. Hepatology. 2022;76:1013\u201329.","journal-title":"Hepatology"},{"key":"1308_CR249","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s43018-023-00624-w","volume":"4","author":"C Zheng","year":"2023","unstructured":"Zheng C, Snow BE, Elia AJ, Nechanitzky R, Dominguez-Brauer C, Liu S, et al. Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma. Nat Cancer. 2023;4:1437\u201354.","journal-title":"Nat Cancer"},{"key":"1308_CR250","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41423-024-01215-0","volume":"21","author":"S Wang","year":"2024","unstructured":"Wang S, Meng L, Xu N, Chen H, Xiao Z, Lu D, et al. Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells. Cell Mol Immunol. 2024;21:1296\u2013308.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR251","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch M, Pruner KB, Shehata L, Pepper M. In Vivo CD4+ T-cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol. 2020;38:705\u201325.","journal-title":"Annu Rev Immunol"},{"key":"1308_CR252","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/cmi.2010.5","volume":"7","author":"F Lafdil","year":"2010","unstructured":"Lafdil F, Miller AM, Ki SH, Gao B. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol. 2010;7:250\u20134.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR253","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev-immunol-101819-092536","volume":"39","author":"S Majumder","year":"2021","unstructured":"Majumder S, McGeachy MJ. IL-17 in the pathogenesis of disease: good intentions gone awry. Annu Rev Immunol. 2021;39:537\u201356.","journal-title":"Annu Rev Immunol"},{"key":"1308_CR254","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","volume":"50","author":"JP Zhang","year":"2009","unstructured":"Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980\u20139.","journal-title":"J Hepatol"},{"key":"1308_CR255","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","volume":"8","author":"L Huangfu","year":"2023","unstructured":"Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023;8:402.","journal-title":"Signal Transduct Target Ther"},{"key":"1308_CR256","doi-asserted-by":"publisher","first-page":"11315","DOI":"10.1002\/cam4.5841","volume":"12","author":"X Zou","year":"2023","unstructured":"Zou X, Xu Q, You R, Yin G. Correlation and efficacy of TACE combined with lenvatinib plus PD \u20101 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Med. 2023;12:11315\u201333.","journal-title":"Cancer Med"},{"key":"1308_CR257","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.7150\/ijbs.38925","volume":"16","author":"Y Wu","year":"2020","unstructured":"Wu Y, Min J, Ge C, Shu J, Tian D, Yuan Y, et al. Interleukin 22 in liver injury, inflammation and cancer. Int J Biol Sci. 2020;16:2405\u201313.","journal-title":"Int J Biol Sci"},{"key":"1308_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40078-8","volume":"9","author":"HL Lee","year":"2019","unstructured":"Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, et al. Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep. 2019;9:3260.","journal-title":"Sci Rep"},{"key":"1308_CR259","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.clinre.2020.01.009","volume":"44","author":"J Shi","year":"2020","unstructured":"Shi J, Wang Y, Wang F, Zhu Z, Gao Y, Zhang Q, et al. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2020;44:855\u201364.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1308_CR260","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","volume":"143","author":"F Meng","year":"2012","unstructured":"Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143:765\u2013776.e3.","journal-title":"Gastroenterology"},{"key":"1308_CR261","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.7150\/thno.45988","volume":"10","author":"Q Zheng","year":"2020","unstructured":"Zheng Q, Martin RC, Shi X, Pandit H, Yu Y, Liu X, et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics. 2020;10:9923\u201336.","journal-title":"Theranostics"},{"key":"1308_CR262","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","volume":"30","author":"AL Gomes","year":"2016","unstructured":"Gomes AL, Teijeiro A, Bur\u00e9n S, Tummala KS, Yilmaz M, Waisman A, et al. Metabolic inflammation-associated IL-17A Causes nonalcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30:161\u201375.","journal-title":"Cancer Cell"},{"key":"1308_CR263","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/s-0041-1730926","volume":"41","author":"N Li","year":"2021","unstructured":"Li N, Yamamoto G, Fuji H, Kisseleva T. Interleukin-17 in liver disease pathogenesis. Semin Liver Dis. 2021;41:507\u201315.","journal-title":"Semin Liver Dis"},{"key":"1308_CR264","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2019.12.016","volume":"72","author":"HY Ma","year":"2020","unstructured":"Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol. 2020;72:946\u201359.","journal-title":"J Hepatol"},{"key":"1308_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100386","volume":"4","author":"C Nalkurthi","year":"2022","unstructured":"Nalkurthi C, Schroder WA, Melino M, Irvine KM, Nyuydzefe M, Chen W, et al. ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Rep. 2022;4:100386.","journal-title":"JHEP Rep"},{"key":"1308_CR266","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.31046","volume":"72","author":"JP Arab","year":"2020","unstructured":"Arab JP, Sehrawat TS, Simonetto DA, Verma VK, Feng D, Tang T, et al. An open\u2010label, dose\u2010escalation study to assess the safety and efficacy of IL\u201022 agonist F\u2010652 in patients with alcohol\u2010associated hepatitis. Hepatology. 2020;72:441\u201353.","journal-title":"Hepatology"},{"key":"1308_CR267","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.3390\/nu14204434","volume":"14","author":"J Chen","year":"2022","unstructured":"Chen J, Zhou H, Jin H, Liu K. Role of inflammatory factors in mediating the effect of lipids on nonalcoholic fatty liver disease: a two-step, multivariable mendelian randomization study. Nutrients. 2022;14:4434.","journal-title":"Nutrients"},{"key":"1308_CR268","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131277","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu J, Ma HY, Liu X, Rosenthal S, Baglieri J, McCubbin R, et al. Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice. JCI Insight. 2020;5:e131277.","journal-title":"JCI Insight"},{"key":"1308_CR269","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ebiom.2019.02.050","volume":"41","author":"Y Liu","year":"2019","unstructured":"Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, et al. NCR\u2212 group 3 innate lymphoid cells orchestrate IL-23\/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine. 2019;41:333\u201344.","journal-title":"EBioMedicine"},{"key":"1308_CR270","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109551","volume":"120","author":"J Wang","year":"2019","unstructured":"Wang J, Lu L, Luo Z, Li W, Lu Y, Tang Q, et al. miR-383 inhibits cell growth and promotes cell apoptosis in hepatocellular carcinoma by targeting IL-17 via STAT3 signaling pathway. Biomed Pharmacother. 2019;120:109551.","journal-title":"Biomed Pharmacother"},{"key":"1308_CR271","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","volume":"19","author":"TKW Lee","year":"2022","unstructured":"Lee TKW, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma\u2014from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022;19:26\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1308_CR272","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hep.29778","volume":"68","author":"H Zheng","year":"2018","unstructured":"Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, et al. Single\u2010cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68:127\u201340.","journal-title":"Hepatology"},{"key":"1308_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35291-5","volume":"13","author":"L Ma","year":"2022","unstructured":"Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M, et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022;13:7533.","journal-title":"Nat Commun"},{"key":"1308_CR274","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 2019;36:418\u2013430.e6.","journal-title":"Cancer Cell"},{"key":"1308_CR275","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3693","volume":"26","author":"J Ni","year":"2024","unstructured":"Ni J, Fu S, Wang Z, Ding W, Huang J, Guo X, et al. Interleukin\u201017A educated hepatic stellate cells promote hepatocellular carcinoma occurrence through fibroblast activation protein expression. J Gene Med. 2024;26:e3693.","journal-title":"J Gene Med"},{"key":"1308_CR276","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jconrel.2020.01.051","volume":"321","author":"JC Wischhusen","year":"2020","unstructured":"Wischhusen JC, Chowdhury SM, Lee T, Wang H, Bachawal S, Devulapally R, et al. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. J Control Release. 2020;321:272\u201384.","journal-title":"J Control Release"},{"key":"1308_CR277","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.7150\/ijbs.70408","volume":"18","author":"I Gasmi","year":"2022","unstructured":"Gasmi I, Machou C, Rodrigues A, Brouillet A, Nguyen TC, Rousseau B, et al. Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through MIR-122 downregulation with increased risk of primary liver cancer initiation. Int J Biol Sci. 2022;18:1944\u201360.","journal-title":"Int J Biol Sci"},{"key":"1308_CR278","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jhep.2019.08.034","volume":"71","author":"Y Wei","year":"2019","unstructured":"Wei Y, Shi D, Liang Z, Liu Y, Li Y, Xing Y, et al. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol. 2019;71:1206\u201315.","journal-title":"J Hepatol"},{"key":"1308_CR279","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109475","volume":"113","author":"EE Abd El-Fattah","year":"2022","unstructured":"Abd El-Fattah EE, Selim HM. Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. Int Immunopharmacol. 2022;113:109475.","journal-title":"Int Immunopharmacol"},{"key":"1308_CR280","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/hep4.1145","volume":"2","author":"A Guillot","year":"2018","unstructured":"Guillot A, Gasmi I, Brouillet A, Ait\u2010Ahmed Y, Calderaro J, Ruiz I, et al. Interleukins\u201017 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. Hepatol Commun. 2018;2:329\u201343.","journal-title":"Hepatol Commun"},{"key":"1308_CR281","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jgh.12032","volume":"28","author":"X Kong","year":"2013","unstructured":"Kong X, Feng D, Mathews S, Gao B. Hepatoprotective and anti\u2010fibrotic functions of interleukin\u201022: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol. 2013;28:56\u201360.","journal-title":"J Gastroenterol Hepatol"},{"key":"1308_CR282","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.7150\/ijbs.86767","volume":"19","author":"W Jia","year":"2023","unstructured":"Jia W, Liang S, Lin W, Li S, Yuan J, Jin M, et al. Hypoxia-induced exosomes facilitate lung premetastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-\u03baB pathway. Int J Biol Sci. 2023;19:4744\u201362.","journal-title":"Int J Biol Sci"},{"key":"1308_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05879-w","volume":"14","author":"H Ren","year":"2023","unstructured":"Ren H, Chen Y, Zhu Z, Xia J, Liu S, Hu Y, et al. FOXO1 regulates Th17 cell-mediated hepatocellular carcinoma recurrence after hepatic ischemia\u2012reperfusion injury. Cell Death Dis. 2023;14:367.","journal-title":"Cell Death Dis"},{"key":"1308_CR284","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/1878-0261.12306","volume":"12","author":"Q Xu","year":"2018","unstructured":"Xu Q, Yu J, Guo X, Hou G, Yuan S, Yang Y, et al. IL \u201017A promotes the invasion\u2013metastasis cascade via the AKT pathway in hepatocellular carcinoma. Mol Oncol. 2018;12:936\u201352.","journal-title":"Mol Oncol"},{"key":"1308_CR285","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215977","volume":"552","author":"YH Lee","year":"2023","unstructured":"Lee YH, Chuah S, Nguyen PHD, Lim CJ, Lai HLH, Wasser M, et al. IFN\u03b3\u2212IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Lett. 2023;552:215977.","journal-title":"Cancer Lett"},{"key":"1308_CR286","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.bbrc.2019.11.134","volume":"522","author":"J Li","year":"2020","unstructured":"Li J, Zeng M, Yan K, Yang Y, Li H, Xu X. IL-17 promotes hepatocellular carcinoma through inhibiting apoptosis induced by IFN-\u03b3. Biochem Biophys Res Commun. 2020;522:525\u201331.","journal-title":"Biochem Biophys Res Commun"},{"key":"1308_CR287","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10:346\u201359.","journal-title":"Liver Cancer"},{"key":"1308_CR288","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/gutjnl-2023-331342","volume":"73","author":"N Cai","year":"2024","unstructured":"Cai N, Cheng K, Ma Y, Liu S, Tao R, Li Y, et al. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T-cell-mediated antitumour immunity and improves anti-PD-1 efficacy. Gut. 2024;73:985\u201399.","journal-title":"Gut"},{"key":"1308_CR289","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","volume":"159","author":"DKC Chiu","year":"2020","unstructured":"Chiu DKC, Yuen VWH, Cheu JWS, Wei LL, Ting V, Fehlings M, et al. Hepatocellular carcinoma cells upregulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology. 2020;159:609\u201323.","journal-title":"Gastroenterology"},{"key":"1308_CR290","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01759-1","volume":"22","author":"Z Hu","year":"2023","unstructured":"Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y, et al. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023;22:55.","journal-title":"Mol Cancer"},{"key":"1308_CR291","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/HEP.0000000000000025","volume":"78","author":"S Wang","year":"2023","unstructured":"Wang S, Wang R, Xu N, Wei X, Yang Y, Lian Z, et al. SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology. 2023;78:1064\u201378.","journal-title":"Hepatology"},{"key":"1308_CR292","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43988-4","volume":"14","author":"X Gu","year":"2023","unstructured":"Gu X, Wei H, Suo C, Shen S, Zhu C, Chen L, et al. Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion. Nat Commun. 2023;14:8154.","journal-title":"Nat Commun"},{"key":"1308_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21804-1","volume":"12","author":"MH Hung","year":"2021","unstructured":"Hung MH, Lee JS, Ma C, Diggs LP, Heinrich S, Chang CW, et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat Commun. 2021;12:1455.","journal-title":"Nat Commun"},{"key":"1308_CR294","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00995-8","volume":"14","author":"JY Hong","year":"2022","unstructured":"Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intratumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med. 2022;14:1.","journal-title":"Genome Med"},{"key":"1308_CR295","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.ccell.2024.10.012","volume":"42","author":"CX Huang","year":"2024","unstructured":"Huang CX, Lao XM, Wang XY, Ren YZ, Lu YT, Shi W, et al. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell. 2024;42:2082\u20132097.e10.","journal-title":"Cancer Cell"},{"key":"1308_CR296","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/gutjnl-2024-332902","volume":"74","author":"J Chen","year":"2025","unstructured":"Chen J, Jiang Y, Hou M, Liu C, Liu E, Zong Y, et al. Nuclear translocation of plasma membrane protein ADCY7 potentiates T-cell-mediated antitumour immunity in HCC. Gut. 2025;74:128\u201340.","journal-title":"Gut"},{"key":"1308_CR297","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77:748\u201360.","journal-title":"J Hepatol"},{"key":"1308_CR298","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","volume":"76","author":"Y Gao","year":"2022","unstructured":"Gao Y, You M, Fu J, Tian M, Zhong X, Du C, et al. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J Hepatol. 2022;76:148\u201359.","journal-title":"J Hepatol"},{"key":"1308_CR299","doi-asserted-by":"crossref","unstructured":"Luo X, Huang W, Li S, Sun M, Hu D, Jiang J, et al. SOX12 facilitates hepatocellular carcinoma progression and metastasis through promoting regulatory T\u2010cells infiltration and immunosuppression. Adv Sci. 2024;11:2310304.","DOI":"10.1002\/advs.202310304"},{"key":"1308_CR300","doi-asserted-by":"publisher","first-page":"e002787","DOI":"10.1136\/jitc-2021-002787","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang Z, He L, Li W, Xu C, Zhang J, Wang D, et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer. 2021;9:e002787.","journal-title":"J Immunother Cancer"},{"key":"1308_CR301","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti\u2013programmed cell death\u20101 in HCC. Hepatology. 2021;74:2544\u201360.","journal-title":"Hepatology"},{"key":"1308_CR302","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202407517","volume":"11","author":"Z Liu","year":"2024","unstructured":"Liu Z, Lin X, Zhang D, Guo D, Tang W, Yu X, et al. Increased PRP19 in hepatocyte impedes B-cell function to promote hepatocarcinogenesis. Adv Sci. 2024;11:2407517.","journal-title":"Adv Sci"},{"key":"1308_CR303","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/hep.31889","volume":"74","author":"F Barrow","year":"2021","unstructured":"Barrow F, Khan S, Wang H, Revelo XS. The emerging role of B cells in the pathogenesis of NAFLD. Hepatology. 2021;74:2277\u201386.","journal-title":"Hepatology"},{"key":"1308_CR304","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.563","volume":"5","author":"Q Sun","year":"2024","unstructured":"Sun Q, Gao R, Lin Y, Zhou X, Wang T, He J. Leveraging single\u2010cell RNA\u2010seq for uncovering na\u00efve B cells associated with better prognosis of hepatocellular carcinoma. MedComm. 2024;5:e563.","journal-title":"MedComm"},{"key":"1308_CR305","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/hep.32442","volume":"77","author":"Z Lu","year":"2023","unstructured":"Lu Z, Liu R, Wang Y, Jiao M, Li Z, Wang Z, et al. Ten\u2010eleven translocation\u20102 inactivation restrains IL\u201010\u2010producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology. 2023;77:745\u201359.","journal-title":"Hepatology"},{"key":"1308_CR306","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101189","volume":"6","author":"N Petriv","year":"2024","unstructured":"Petriv N, Suo H, Hochnadel I, Timrott K, Bondarenko N, Neubert L, et al. Essential roles of B-cell subsets in the progression of MASLD and HCC. JHEP Rep. 2024;6:101189.","journal-title":"JHEP Rep"},{"key":"1308_CR307","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imm.13101","volume":"158","author":"CC Liu","year":"2019","unstructured":"Liu CC, Steen CB, Newman AM. Computational approaches for characterizing the tumor immune microenvironment. Immunology. 2019;158:70\u201384.","journal-title":"Immunology"},{"key":"1308_CR308","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.7150\/ijbs.92525","volume":"20","author":"H Yan","year":"2024","unstructured":"Yan H, Ju X, Huang A, Yuan J. Advancements in technology for characterizing the tumor immune microenvironment. Int J Biol Sci. 2024;20:2151\u201367.","journal-title":"Int J Biol Sci"},{"key":"1308_CR309","doi-asserted-by":"crossref","unstructured":"Guillot A, Buch C, Jourdan T. Kupffer cell and monocyte-derived macrophage identification by immunofluorescence on Formalin-Fixed, Paraffin-Embedded (FFPE) mouse liver sections. In: Aouadi M, Azzimato V, editors. Kupffer Cells [Internet]. New York, NY: Springer US; 2020 [cited 2024 Jul 10]. [45\u201353 p.]. (Methods in Molecular Biology; vol. 2164). Available from: http:\/\/link.springer.com\/10.1007\/978-1-0716-0704-6_6.","DOI":"10.1007\/978-1-0716-0704-6_6"},{"key":"1308_CR310","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.3390\/cancers12092449","volume":"12","author":"A Guillot","year":"2020","unstructured":"Guillot A, Kohlhepp M, Bruneau A, Heymann F, Tacke F. Deciphering the immune microenvironment on a single archival formalin-fixed paraffin-embedded tissue section by an immediately implementable multiplex fluorescence immunostaining protocol. Cancers. 2020;12:2449.","journal-title":"Cancers"},{"key":"1308_CR311","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157780","volume":"132","author":"J Ma","year":"2022","unstructured":"Ma J, Guillot A, Yang Z, Mackowiak B, Hwang S, Park O, et al. Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. J Clin Investig. 2022;132:e157780.","journal-title":"J Clin Investig"},{"key":"1308_CR312","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166954","volume":"133","author":"D Feng","year":"2023","unstructured":"Feng D, Xiang X, Guan Y, Guillot A, Lu H, Chang C, et al. Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models. J Clin Investig. 2023;133:e166954.","journal-title":"J Clin Investig"},{"key":"1308_CR313","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/HEP.0000000000000590","volume":"79","author":"Y Liu","year":"2024","unstructured":"Liu Y, Xiao J, Cai J, Li R, Sui X, Zhang J, et al. Single-cell immune profiling of mouse liver aging reveals Cxcl2 + macrophages recruit neutrophils to aggravate liver injury. Hepatology. 2024;79:589\u2013605.","journal-title":"Hepatology"},{"key":"1308_CR314","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","volume":"72","author":"C Montironi","year":"2023","unstructured":"Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, et al. Inflamed and noninflamed classes of HCC: a revised immunogenomic classification. Gut. 2023;72:129\u201340.","journal-title":"Gut"},{"key":"1308_CR315","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/hep.32585","volume":"77","author":"X Zeng","year":"2023","unstructured":"Zeng X, Liao G, Li S, Liu H, Zhao X, Li S, et al. Eliminating METTL1\u2010mediated accumulation of PMN\u2010MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. Hepatology. 2023;77:1122\u201338.","journal-title":"Hepatology"},{"key":"1308_CR316","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, et al. The single\u2010cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci. 2023;10:2203699.","journal-title":"Adv Sci"},{"key":"1308_CR317","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jhep.2023.10.006","volume":"80","author":"L Zhang","year":"2024","unstructured":"Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, et al. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. J Hepatol. 2024;80:82\u201398. Jan","journal-title":"J Hepatol"},{"key":"1308_CR318","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/cancers14081861","volume":"14","author":"DE Millian","year":"2022","unstructured":"Millian DE, Saldarriaga OA, Wanninger T, Burks JK, Rafati YN, Gosnell J, et al. Cutting-edge platforms for analysis of immune cells in the hepatic microenvironment\u2014focus on tumor-associated macrophages in hepatocellular carcinoma. Cancers. 2022;14:1861.","journal-title":"Cancers"},{"key":"1308_CR319","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1033497","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang Y, Sun L, Chen Z, Liu W, Xu Q, Liu F, et al. The immune-metabolic crosstalk between CD3+C1q+TAM and CD8+T cells associated with relapse-free survival in HCC. Front Immunol. 2023;14:1033497.","journal-title":"Front Immunol"},{"key":"1308_CR320","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.800","volume":"12","author":"W He","year":"2022","unstructured":"He W, Hu Y, Chen D, Li Y, Ye D, Zhao Q, et al. Hepatocellular carcinoma\u2010infiltrating \u03b3\u03b4 T cells are functionally defected and allogenic V\u03b42 + \u03b3\u03b4 T-cell can be a promising complement. Clin Transl Med. 2022;12:e800.","journal-title":"Clin Transl Med"},{"key":"1308_CR321","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","volume":"72","author":"Z Xiong","year":"2023","unstructured":"Xiong Z, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, et al. Targeting PPAR-gamma counteracts tumor adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72:1758\u201373.","journal-title":"Gut"},{"key":"1308_CR322","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li M, Wang L, Cong L, Wong CC, Zhang X, Chen H, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatol Balt Md. 2024;79:560\u201374.","journal-title":"Hepatol Balt Md"},{"key":"1308_CR323","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Chen X, Feng L, Yang Z, Xiao L, Xiang B, et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discov. 2025;11:1.","journal-title":"Cell Discov"},{"key":"1308_CR324","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24386-0","volume":"12","author":"YF Sun","year":"2021","unstructured":"Sun YF, Wu L, Liu SP, Jiang MM, Hu B, Zhou KQ, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun. 2021;12:4091.","journal-title":"Nat Commun"},{"key":"1308_CR325","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.7150\/thno.71873","volume":"12","author":"YF Wang","year":"2022","unstructured":"Wang YF, Yuan SX, Jiang H, Li ZX, Yin HZ, Tan J, et al. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment. Theranostics. 2022;12:4163\u201380.","journal-title":"Theranostics"},{"key":"1308_CR326","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/HEP.0000000000000600","volume":"79","author":"E Maestri","year":"2024","unstructured":"Maestri E, Kedei N, Khatib S, Forgues M, Ylaya K, Hewitt SM, et al. Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. Hepatol Balt Md. 2024;79:768\u201379.","journal-title":"Hepatol Balt Md"},{"key":"1308_CR327","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00535-z","volume":"12","author":"N Zhang","year":"2024","unstructured":"Zhang N, Yang X, Piao M, Xun Z, Wang Y, Ning C, et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res. 2024;12:26.","journal-title":"Biomark Res"},{"key":"1308_CR328","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00752-1","volume":"8","author":"J Ye","year":"2024","unstructured":"Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L, et al. Single cell-spatial transcriptomics and bulk multiomics analysis of heterogeneity and ecosystems in hepatocellular carcinoma. NPJ Precis Oncol. 2024;8:262.","journal-title":"NPJ Precis Oncol"},{"key":"1308_CR329","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100198","volume":"3","author":"S Nuciforo","year":"2021","unstructured":"Nuciforo S, Heim MH. Organoids to model liver disease. JHEP Rep. 2021;3:100198.","journal-title":"JHEP Rep"},{"key":"1308_CR330","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302640","volume":"10","author":"Z Zou","year":"2023","unstructured":"Zou Z, Lin Z, Wu C, Tan J, Zhang J, Peng Y, et al. Micro\u2010engineered organoid\u2010on\u2010a\u2010chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Adv Sci. 2023;10:2302640.","journal-title":"Adv Sci"},{"key":"1308_CR331","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13046-024-02957-5","volume":"43","author":"M Pan","year":"2024","unstructured":"Pan M, Luo M, Liu L, Chen Y, Cheng Z, Wang K, et al. EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL. J Exp Clin Cancer Res. 2024;43:35.","journal-title":"J Exp Clin Cancer Res"},{"key":"1308_CR332","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/15548627.2022.2117893","volume":"19","author":"J Pan","year":"2023","unstructured":"Pan J, Zhang M, Dong L, Ji S, Zhang J, Zhang S, et al. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy. 2023;19:1184\u201398.","journal-title":"Autophagy"},{"key":"1308_CR333","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121527","volume":"284","author":"JTC Lim","year":"2022","unstructured":"Lim JTC, Kwang LG, Ho NCW, Toh CCM, Too NSH, Hooi L, et al. Hepatocellular carcinoma organoid cocultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment. Biomaterials. 2022;284:121527.","journal-title":"Biomaterials"},{"key":"1308_CR334","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41392-022-01248-9","volume":"8","author":"XP Tan","year":"2023","unstructured":"Tan XP, He Y, Yang J, Wei X, Fan YL, Zhang GG, et al. Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression. Signal Transduct Target Ther. 2023;8:14.","journal-title":"Signal Transduct Target Ther"},{"key":"1308_CR335","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206798","volume":"10","author":"C Zheng","year":"2023","unstructured":"Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, et al. Donafenib and GSK\u2010J4 synergistically induce ferroptosis in liver cancer by upregulating HMOX1 expression. Adv Sci. 2023;10:2206798.","journal-title":"Adv Sci"},{"key":"1308_CR336","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.32802","volume":"78","author":"YK Lam","year":"2023","unstructured":"Lam YK, Yu J, Huang H, Ding X, Wong AM, Leung HH, et al. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk. Hepatology. 2023;78:727\u201340.","journal-title":"Hepatology"},{"key":"1308_CR337","doi-asserted-by":"publisher","first-page":"23306","DOI":"10.18632\/oncotarget.4202","volume":"6","author":"L He","year":"2015","unstructured":"He L, Tian DA, Li PY, He XX. Mouse models of liver cancer: progress and recommendations. Oncotarget. 2015;6:23306\u201322.","journal-title":"Oncotarget"},{"key":"1308_CR338","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jhep.2022.07.029","volume":"77","author":"N Rosenberg","year":"2022","unstructured":"Rosenberg N, Van Haele M, Lanton T, Brashi N, Bromberg Z, Adler H, et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol. 2022;77:1631\u201341.","journal-title":"J Hepatol"},{"key":"1308_CR339","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/gutjnl-2022-327924","volume":"72","author":"Y Fu","year":"2023","unstructured":"Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, et al. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut. 2023;72:1942\u201358.","journal-title":"Gut"},{"key":"1308_CR340","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-023-02609-0","volume":"42","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu Q, Deng F, Zheng Z, Luo J, Wang P, et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res. 2023;42:38.","journal-title":"J Exp Clin Cancer Res"},{"key":"1308_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27452-9","volume":"12","author":"F Yao","year":"2021","unstructured":"Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, et al. A targetable LIFR\u2212NF-\u03baB\u2212LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun. 2021;12:7333.","journal-title":"Nat Commun"},{"key":"1308_CR342","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang J, Liu D, Wang Y, Liu L, Li J, Yuan J, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy. Gut. 2022;71:734\u201345.","journal-title":"Gut"},{"key":"1308_CR343","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/hep.32707","volume":"77","author":"DJ Zabransky","year":"2023","unstructured":"Zabransky DJ, Danilova L, Leatherman JM, Lopez\u2010Vidal TY, Sanchez J, Charmsaz S, et al. Profiling of syngeneic mouse HCC tumor models as a framework to understand anti\u2013PD\u20101 sensitive tumor microenvironments. Hepatology. 2023;77:1566\u201379.","journal-title":"Hepatology"},{"key":"1308_CR344","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1158\/1078-0432.CCR-19-3275","volume":"26","author":"D Mathur","year":"2020","unstructured":"Mathur D, Root AR, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, et al. A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers. Clin Cancer Res. 2020;26:2188\u2013202.","journal-title":"Clin Cancer Res"},{"key":"1308_CR345","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","volume":"69","author":"T Tsuchida","year":"2018","unstructured":"Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69:385\u201395.","journal-title":"J Hepatol"},{"key":"1308_CR346","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jhep.2023.03.041","volume":"79","author":"D Povero","year":"2023","unstructured":"Povero D, Chen Y, Johnson SM, McMahon CE, Pan M, Bao H, et al. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. J Hepatol. 2023;79:378\u201393.","journal-title":"J Hepatol"},{"key":"1308_CR347","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.cmet.2022.07.010","volume":"34","author":"P Zhang","year":"2022","unstructured":"Zhang P, Chen Z, Kuang H, Liu T, Zhu J, Zhou L, et al. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell Metab. 2022;34:1359\u20131376.e7.","journal-title":"Cell Metab"},{"key":"1308_CR348","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/gutjnl-2023-330826","volume":"73","author":"L Bu","year":"2024","unstructured":"Bu L, Zhang Z, Chen J, Fan Y, Guo J, Su Y, et al. High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT. Gut. 2024;73:1156\u201368.","journal-title":"Gut"},{"key":"1308_CR349","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","volume":"118","author":"JL Petrick","year":"2018","unstructured":"Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G, Beane-Freeman LE, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. Br J Cancer. 2018;118:1005\u201312.","journal-title":"Br J Cancer"},{"key":"1308_CR350","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/annonc\/mdu020","volume":"25","author":"F Turati","year":"2014","unstructured":"Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol. 2014;25:1526\u201335.","journal-title":"Ann Oncol"},{"key":"1308_CR351","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/s-0040-1708876","volume":"40","author":"M Matsuda","year":"2020","unstructured":"Matsuda M, Seki E. Hepatic stellate cell\u2013macrophage crosstalk in liver fibrosis and carcinogenesis. Semin Liver Dis. 2020;40:307\u201320.","journal-title":"Semin Liver Dis"},{"key":"1308_CR352","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","volume":"72","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Greten TF. Gut microbiome in HCC\u2014mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230\u20138.","journal-title":"J Hepatol"},{"key":"1308_CR353","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carri\u00e9","year":"2019","unstructured":"Ganne-Carri\u00e9 N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70:284\u201393.","journal-title":"J Hepatol"},{"key":"1308_CR354","doi-asserted-by":"publisher","first-page":"9679","DOI":"10.3390\/ijms23179679","volume":"23","author":"R Sasaki-Tanaka","year":"2022","unstructured":"Sasaki-Tanaka R, Ray R, Moriyama M, Ray RB, Kanda T. Molecular changes in relation to alcohol consumption and hepatocellular carcinoma. Int J Mol Sci. 2022;23:9679.","journal-title":"Int J Mol Sci"},{"key":"1308_CR355","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1225821","volume":"14","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Ruff SM, Pawlik TM. The effect of liver disease on hepatic microenvironment and implications for immune therapy. Front Pharm. 2023;14:1225821.","journal-title":"Front Pharm"},{"key":"1308_CR356","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.mam.2007.10.001","volume":"29","author":"T Mello","year":"2008","unstructured":"Mello T, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Asp Med. 2008;29:17\u201321.","journal-title":"Mol Asp Med"},{"key":"1308_CR357","first-page":"1","volume":"000","author":"Q Wang","year":"2021","unstructured":"Wang Q, Chang B, Li X, Zou Z. Role of ALDH2 in hepatic disorders: gene polymorphism and disease pathogenesis. J Clin Transl Hepatol. 2021;000:1\u20139.","journal-title":"J Clin Transl Hepatol"},{"key":"1308_CR358","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.nutres.2018.10.002","volume":"61","author":"M Rizk","year":"2019","unstructured":"Rizk M, Guilloteau A, Mouillot T, Thiefin G, Bronowicki JP, Richou C, et al. Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients. Nutr Res. 2019;61:82\u201394.","journal-title":"Nutr Res"},{"key":"1308_CR359","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4251\/wjgo.v13.i10.1440","volume":"13","author":"A Ruiz-Marg\u00e1in","year":"2021","unstructured":"Ruiz-Marg\u00e1in A, Rom\u00e1n-Calleja BM, Moreno-Guill\u00e9n P, Gonz\u00e1lez-Regueiro JA, K\u00fasulas-Delint D, Campos-Murgu\u00eda A, et al. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol. 2021;13:1440\u201352.","journal-title":"World J Gastrointest Oncol"},{"key":"1308_CR360","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","volume":"175","author":"V Singh","year":"2018","unstructured":"Singh V, Yeoh BS, Chassaing B, Xiao X, Saha P, Aguilera Olvera R, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell. 2018;175:679\u2013694.e22.","journal-title":"Cell"},{"key":"1308_CR361","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/19490976.2020.1743492","volume":"11","author":"V Singh","year":"2020","unstructured":"Singh V, Yeoh BS, Abokor AA, Golonka RM, Tian Y, Patterson AD, et al. Vancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota. Gut Microbes. 2020;11:1077\u201391.","journal-title":"Gut Microbes"},{"key":"1308_CR362","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1053\/j.gastro.2022.08.033","volume":"163","author":"BS Yeoh","year":"2022","unstructured":"Yeoh BS, Saha P, Golonka RM, Zou J, Petrick JL, Abokor AA, et al. Enterohepatic shunt-driven cholemia predisposes to liver cancer. Gastroenterology. 2022;163:1658\u20131671.e16.","journal-title":"Gastroenterology"},{"key":"1308_CR363","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1308_CR364","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"1308_CR365","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"key":"1308_CR366","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317\u201370.","journal-title":"Hepatol Int"},{"key":"1308_CR367","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomized, open-label, multicenter, phase 3 trial. Lancet. 2023;402:1835\u201347.","journal-title":"Lancet"},{"key":"1308_CR368","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomized, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22:977\u201390.","journal-title":"Lancet Oncol"},{"key":"1308_CR369","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024;25:1465\u201375.","journal-title":"Lancet Oncol"},{"key":"1308_CR370","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"JL Raoul","year":"2019","unstructured":"Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28\u201336.","journal-title":"Cancer Treat Rev"},{"key":"1308_CR371","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatol Balt Md. 2016;64:106\u201316.","journal-title":"Hepatol Balt Md"},{"key":"1308_CR372","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000522547","volume":"11","author":"M Kudo","year":"2022","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. Liver Cancer. 2022;11:354\u201367.","journal-title":"Liver Cancer"},{"key":"1308_CR373","doi-asserted-by":"publisher","first-page":"LBA432","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432","volume":"42","author":"R Lencioni","year":"2024","unstructured":"Lencioni R, Kudo M, Erinjeri J, Qin S, Ren Z, Chan S, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024;42:LBA432\u2013LBA432.","journal-title":"J Clin Oncol"},{"key":"1308_CR374","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00270-021-03031-9","volume":"45","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, et al. Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Cardiovasc Interv Radio. 2022;45:405\u201312.","journal-title":"Cardiovasc Interv Radio"},{"key":"1308_CR375","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.14.","journal-title":"N Engl J Med"},{"key":"1308_CR376","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol [Internet]. 2021 Dec 10 [cited 2022 Feb 14];0(0). Available from: https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(21)02241-8\/fulltext."},{"key":"1308_CR377","doi-asserted-by":"crossref","unstructured":"Abou-Alfa Ghassan K, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"1308_CR378","doi-asserted-by":"publisher","first-page":"LBA4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","volume":"42","author":"PR Galle","year":"2024","unstructured":"Galle PR, Decaens T, Kudo M, Qin S, Fonseca L, Sangro B, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. J Clin Oncol. 2024;42:LBA4008\u2013LBA4008.","journal-title":"J Clin Oncol"},{"key":"1308_CR379","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102167","volume":"47","author":"H Giudicelli","year":"2023","unstructured":"Giudicelli H, Roux C, Monsel A, Conti F, Scatton O, Allaire M. Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation. Clin Res Hepatol Gastroenterol. 2023;47:102167.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1308_CR380","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"1308_CR381","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/liv.15419","volume":"43","author":"S Kayali","year":"2023","unstructured":"Kayali S, Pasta A, Plaz Torres MC, Jaffe A, Strazzabosco M, Marenco S, et al. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver Int. 2023;43:8\u201317.","journal-title":"Liver Int"},{"key":"1308_CR382","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","volume":"79","author":"T Meyer","year":"2023","unstructured":"Meyer T, Galani S, Lopes A, Vogel A. Etiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with nonviral liver disease. J Hepatol. 2023;79:e73\u20136.","journal-title":"J Hepatol"},{"key":"1308_CR383","doi-asserted-by":"crossref","unstructured":"Copil FD, Campani C, Lequoy M, Sultanik P, Blaise L, Wagner M, et al. No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC. Liver Int. 2024;44:931\u2013943.","DOI":"10.1111\/liv.15833"},{"key":"1308_CR384","first-page":"00304","volume":"S1590-8658","author":"P Sultanik","year":"2024","unstructured":"Sultanik P, Campani C, Larrey E, Campion B, Evain M, Roux C, et al. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Dig Liver Dis. 2024;S1590-8658:00304\u20139.","journal-title":"Dig Liver Dis"},{"key":"1308_CR385","doi-asserted-by":"crossref","unstructured":"D\u2019Alessio A, Fulgenzi CAM, Nishida N, Sch\u00f6nlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child\u2012Pugh A and B cirrhosis: a real-world study. Hepatology. 2022;76:1000\u201312.","DOI":"10.1002\/hep.32554"},{"key":"1308_CR386","doi-asserted-by":"crossref","unstructured":"Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatology. 2024;79:213\u201323.","DOI":"10.1097\/HEP.0000000000000291"},{"key":"1308_CR387","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101120","volume":"6","author":"M Allaire","year":"2024","unstructured":"Allaire M, Sultanik P, Thabut D. Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC. JHEP Rep. 2024;6:101120.","journal-title":"JHEP Rep"},{"key":"1308_CR388","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, Villanueva A, Korangy F, Ruf B, Yarchoan M, Ma L, et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol. 2023;20:780\u201398.","journal-title":"Nat Rev Clin Oncol"},{"key":"1308_CR389","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","volume":"25","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt\/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res J Am Assoc Cancer Res. 2019;25:2021\u20133.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1308_CR390","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, Lindblad KE, Maier B, Sia D, et al. \u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124\u201341.","journal-title":"Cancer Discov"},{"key":"1308_CR391","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.gastro.2019.05.069","volume":"157","author":"A Gougelet","year":"2019","unstructured":"Gougelet A, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, et al. Hepatocellular carcinomas with mutational activation of beta-catenin require choline and can be detected by positron emission tomography. Gastroenterology. 2019;157:807\u201322.","journal-title":"Gastroenterology"},{"key":"1308_CR392","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","volume":"164","author":"PK Haber","year":"2023","unstructured":"Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigveh\u00ed M, Miho M, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2023;164:72\u201388.e18.","journal-title":"Gastroenterology"},{"key":"1308_CR393","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/gutjnl-2024-331956","volume":"73","author":"C Campani","year":"2024","unstructured":"Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch TZ, Rebouissou S, et al. Circulating tumor DNA in patients with hepatocellular carcinoma across tumor stages and treatments. Gut. 2024;73:1870\u201382.","journal-title":"Gut"},{"key":"1308_CR394","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S1470-2045(23)00468-0","volume":"24","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, Klein C, Caruso S, Maille P, Allende DS, M\u00ednguez B, et al. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicenter retrospective study. Lancet Oncol. 2023;24:1411\u201322.","journal-title":"Lancet Oncol"},{"key":"1308_CR395","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.dld.2023.01.161","volume":"55","author":"P Merle","year":"2023","unstructured":"Merle P, Blanc JF, Edeline J, Le Malicot K, Allaire M, Assenat E, et al. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Dig Liver Dis. 2023;55:464\u201370.","journal-title":"Dig Liver Dis"},{"key":"1308_CR396","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56537-y","volume":"16","author":"D Xu","year":"2025","unstructured":"Xu D, Wang H, Bao Q, Jin K, Liu M, Liu W, et al. The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial. Nat Commun. 2025;16:1443.","journal-title":"Nat Commun"},{"key":"1308_CR397","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","volume":"26","author":"RS Finn","year":"2025","unstructured":"Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, et al. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomized, open-label, phase 1b-2, study. Lancet Oncol. 2025;26:214\u201326.","journal-title":"Lancet Oncol"},{"key":"1308_CR398","first-page":"3212","volume":"12","author":"Q Zheng","year":"2020","unstructured":"Zheng Q, Xu J, Gu X, Wu F, Deng J, Cai X, et al. Immune checkpoint targeting TIGIT in hepatocellular carcinoma. Am J Transl Res. 2020;12:3212\u201324.","journal-title":"Am J Transl Res"},{"key":"1308_CR399","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12876-5","volume":"24","author":"Y Guo","year":"2024","unstructured":"Guo Y, Yang X, Xia WL, Zhu WB, Li FT, Hu HT, et al. Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2024;24:1120.","journal-title":"BMC Cancer"},{"key":"1308_CR400","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","volume":"18","author":"Y Sawada","year":"2012","unstructured":"Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res J Am Assoc Cancer Res. 2012;18:3686\u201396.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1308_CR401","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-209","volume":"10","author":"TF Greten","year":"2010","unstructured":"Greten TF, Forner A, Korangy F, N\u2019Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010;10:209.","journal-title":"BMC Cancer"},{"key":"1308_CR402","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11065-0","volume":"23","author":"A Vienot","year":"2023","unstructured":"Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, et al. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized noncomparative phase II study (TERTIO - PRODIGE 82). BMC Cancer. 2023;23:710.","journal-title":"BMC Cancer"},{"key":"1308_CR403","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fonc.2019.00019","volume":"9","author":"M Rizell","year":"2019","unstructured":"Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 trial with the cell-based immune primer ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma. Front Oncol. 2019;9:19.","journal-title":"Front Oncol"},{"key":"1308_CR404","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/vaccines11081357","volume":"11","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, Saeed A, Singh M, Cavalcante L, Sahin IH, Saeed A. A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines. 2023;11:1357.","journal-title":"Vaccines"},{"key":"1308_CR405","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","volume":"38","author":"F Zhou","year":"2018","unstructured":"Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741\u201367.","journal-title":"Med Res Rev"},{"key":"1308_CR406","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26:3979\u201389.","journal-title":"Clin Cancer Res"},{"key":"1308_CR407","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963031","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, et al. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T Cells plus sorafenib, a case report. Front Immunol. 2022;13:963031.","journal-title":"Front Immunol"},{"key":"1308_CR408","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ymthe.2019.04.020","volume":"27","author":"X Wu","year":"2019","unstructured":"Wu X, Luo H, Shi B, Di S, Sun R, Su J, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol Ther. 2019;27:1483\u201394.","journal-title":"Mol Ther"},{"key":"1308_CR409","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, et al. IL-7 and CCL19-secreting CAR-T-cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14:118.","journal-title":"J Hematol Oncol"},{"key":"1308_CR410","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","volume":"39","author":"LL Lu","year":"2023","unstructured":"Lu LL, Xiao SX, Lin ZY, Bai JJ, Li W, Song ZQ, et al. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Cell Biol Toxicol. 2023;39:3101\u201319.","journal-title":"Cell Biol Toxicol"},{"key":"1308_CR411","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200817","volume":"32","author":"L Zhou","year":"2024","unstructured":"Zhou L, Li Y, Zheng D, Zheng Y, Cui Y, Qin L, et al. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. Mol Ther Oncol. 2024;32:200817.","journal-title":"Mol Ther Oncol"},{"key":"1308_CR412","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489649","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Wei S, Xu M, Wu X, Dou W, Li H, et al. CAR-T-cell therapy for hepatocellular carcinoma: current trends and challenges. Front Immunol. 2024;15:1489649.","journal-title":"Front Immunol"},{"key":"1308_CR413","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21:524\u20139.","journal-title":"Nat Med"},{"key":"1308_CR414","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"1308_CR415","doi-asserted-by":"publisher","first-page":"e0317401","DOI":"10.1371\/journal.pone.0317401","volume":"20","author":"L Yang","year":"2025","unstructured":"Yang L, Pham K, Xi Y, Wu Q, Liu D, Robertson KD, et al. Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PloS ONE. 2025;20:e0317401.","journal-title":"PloS ONE"},{"key":"1308_CR416","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang T, Bei C, Hu Z, Li Y. CAR-macrophage: breaking new ground in cellular immunotherapy. Front Cell Dev Biol. 2024;12:1464218.","journal-title":"Front Cell Dev Biol"},{"key":"1308_CR417","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.","journal-title":"Front Immunol"},{"key":"1308_CR418","volume":"39","author":"L Guan","year":"2024","unstructured":"Guan L, Wu S, Zhu Q, He X, Li X, Song G, et al. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma. Biochem Biophys Rep. 2024;39:101741.","journal-title":"Biochem Biophys Rep"},{"key":"1308_CR419","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in preclinical models. Nat Commun. 2025;16:706.","journal-title":"Nat Commun"},{"key":"1308_CR420","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatol Balt Md. 2023;77:1773\u201396.","journal-title":"Hepatol Balt Md"},{"key":"1308_CR421","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M, et al. Integrated multiomics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 2024;42:135\u2013156.e17.","journal-title":"Cancer Cell"},{"key":"1308_CR422","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jhep.2022.01.014","volume":"76","author":"J Calderaro","year":"2022","unstructured":"Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76:1348\u201361.","journal-title":"J Hepatol"},{"key":"1308_CR423","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/HEP.0000000000000553","volume":"79","author":"B Li","year":"2024","unstructured":"Li B, Li Y, Zhou H, Xu Y, Cao Y, Cheng C, et al. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology. 2024;79:289\u2013306.","journal-title":"Hepatology"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01308-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01308-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01308-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T22:02:50Z","timestamp":1759183370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01308-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":423,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1038\/s41423-025-01308-4","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests. Dr. Bin Gao is Associate Editor-in-Chief of Cellular & Molecular Immunology, but he has not been involved in the peer review or the decision-making of the article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}